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Role of Patients’ Perception of Barriers to Taking Medication on Medication Adherence 
Among Patients With Diabetes: Development and Psychometric Evaluation of the 
Murage-Marrero-Monahan Medication Barriers Scale (4M Scale), Patient Characteristics 
Associated With Medication Barriers, and Association of Medication Barriers and 
Cardiovascular Disease (CVD) Risk 
 
Introduction 
Medication adherence remains a problem among Type-2 diabetes (T2D) patients 
despite availability of effective treatments. Three analyses of extant data sets were 
conducted to examine barriers to using medication as prescribed as an alternate  method 
to assess medication adherence: 1) development and psychometric evaluation of the 
Murage-Marrero-Monahan-Medication barriers (4M) scale to assess patients’ perceived 
barriers; 2) patient demographic factors associated with barriers to using medication as 
prescribed, and 3) the association between patients’ perceived barriers to medication use 
and cardiovascular disease (CVD) risk factor control. 
Methods 
Twelve focus groups and a cross-sectional study of 362 T2D patients contributed 
to develop and evaluate psychometric properties of the 4M scale. A cross-sectional 
survey of 964 T2D patients was used for the other two studies. Analysis of covariance 
identified demographic factors associated with reported barriers. Multivariable logistic 
vii 
regression was used to identify barriers associated with CVD risk factors (glucose, blood 
pressure and lipids) categorized as either poor or good control.  
Results 
Exploratory factor analysis with Varimax rotation resulted in a 19-item 4M scale 
with acceptable psychometric properties. As a five-domain (or single-domain) structure, 
coefficient alpha ranged from 0.70 to 0.83 (0.92). Both structures demonstrated 
discriminant validity and known-group validity. Age was inversely associated with all 
identified barriers while income was inversely associated with poor communication with 
providers and side effects. A unit increase in the overall barrier mean score on the 4M 
scale was associated with 92% increase in the odds of having poor control of two or more 
CVD risk factors compared to good control of all three risk factors (adjusted OR=1.92, 
95% CI: 1.16–3.17; p<0.05). 
Conclusion 
The 4M scale demonstrated acceptable psychometric properties in assessing 
barriers to using medication among T2D patients. Poor medication adherence has been 
previously associated with CVD risk. In this study, greater barriers were associated with 
poorer control of CVD risk factors making barriers a potential alternative to medication 
adherence, whose current assessment methods are limited. The 4M scale has the 
advantage to identify specific barriers inhibiting medication use that can facilitate patient-
provider discussions and the development of targeted interventions. 
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CHAPTER 1 
 
INTRODUCTION 
 
As the burden of diabetes continues on an upward trend, it is estimated that more 
than a third of the United States (U.S.) population will have diabetes by 2050 (1). In 2012 
more than 29 million people in the U.S. had diagnosed diabetes, with an additional 89 
million having pre-diabetes, which greatly increases their chances of developing diabetes 
(2). Diabetes has significant social and fiscal burden (3). It costs the U.S. more than 245 
billion dollars annually with direct medical expenditures exceeding 176 billion: twice that 
of people without diabetes (4, 5). 
Whereas most efforts to reduce this burden have focused on early diagnosis and 
aggressive diabetes management among diagnosed patients (5), most of them are not 
achieving optimal outcomes, in spite of a wide array of available treatment options with 
proven efficacy (6-14). In addition to suspected socio-economic factors, medication 
adherence has emerged as a potential explanation of the discrepancy, especially among 
patients who have access to medical care and treatment (10, 12). 
Established evidence that diabetes is a risk factor for cardiovascular disease 
(CVD) – a leading cause of death in the U.S. – explains why most patients with diabetes 
proceed to develop CVD, macrovascular and microvascular complications, and 
eventually premature death (4, 13, 15-20). Again, the less than optimal targets on the 
cardinal CVD risk factors – glycosylated hemoglobin A1c (HbA1c), systolic blood 
pressure (SBP) and low density lipoprotein cholesterol (LDL-c) – despite availability of 
medication has been attributed to poor medication adherence (13, 18-22). 
2 
The need to assess medication adherence in the clinical care of diabetes patients is 
underscored by the findings that higher medication adherence is associated with better 
glycemic control, improved health outcomes, lower healthcare utilization and lower 
healthcare costs (10, 23-28). The need to evaluate medication adherence is further 
illuminated by evidence that medication adherence is a modifiable behavior that can be 
improved with appropriate interventions once identified (29). 
Current methods of assessing medication adherence among patients are limited. 
Direct observations are impractical, direct inquiry is likely to be inaccurate due to social 
pressures influencing responses, metabolic markers are expensive, and pill counts and 
drug possession estimates are mostly not feasible and often inaccurate (30-33). A variety 
of self-reported measures have been used because they are simple to use, less expensive 
and can be accurate – to the extent that they have good validity and reliability and 
patients will correctly respond to them (34). 
Social desirability bias, validity and reliability are major impediments on the 
accuracy of available self-reported measures of medication adherence. This study 
postulates that patients’ perception and reporting of barriers to using medications as 
prescribed by their healthcare providers can indicate possible issues in medication 
adherence. Moreover, by focusing on general responses to medications per se, without 
reference to specific medications, patients may be empowered to describe issues that they 
face without fear of reprimand from their provider. This may help to circumvent the 
pitfalls of patients providing a “socially desirable” but inaccurate response when they are 
directly confronted about their current specific medication use.  
3 
Additionally, understanding patient demographic characteristics associated with 
perceived barriers to medication use would enhance use of the 4M scale with diverse 
populations, avoiding the tendency of trying to assess a heterogeneous population with a 
one size fits all mentality. Finally, understanding the link between patient perceived 
barriers to medication use and CVD risk would support the concept of assessing patients’ 
perceived barriers to using medication as a means to identify issues of poor medication 
adherence in such a manner that possible tailored interventions may be prescribed. 
 
1.1 Conceptual Framework 
Directly confronting patients on their adherence to prescribed medication is likely 
to result in socially desirable responses because of the social pressure inherent in doctor-
patient relationship. Doctors continue to hold a high social status that intimidates many 
persons. As a result, many people do not want to tell their doctor that they are not 
complying with his or her treatment recommendations (35).  For this reason this 
dissertation explores an indirect method of assessing medication adherence without 
directly inquiring from patients about their adherence to specific medications at the point 
in time when the assessment is being made. By taking this approach, it is postulated that 
patients will be more empowered to admit to barriers that they may have experienced at 
some time in their life and by this perspective not having to admit that this is an active 
element in their current treatment. In essence, they can tell the provider that a specific 
barrier has been a problem for them at some time, and by indicating how often the barrier 
occurs, indirectly indicate that the barrier is in fact persistent. When this information is 
combined with laboratory data, the provider is in a better position to discuss possible 
ways to reduce or eliminate the barrier in the present time. 
4 
In this dissertation, barriers are defined as patients’ perceived barriers or obstacles 
to using medications as prescribed by their healthcare provider, and are henceforth 
referred to as barriers. Barriers, like medication adherence, constitute a latent construct 
that influences several behaviors manifested externally by patients (Figure 1.1). The 
study postulates that barriers are inversely related to medication adherence. Therefore, it 
is assumed that an increase in the barriers would result in poor (lower) medication 
adherence whereas a decrease in the barriers would result in good (higher) medication 
adherence. Although studies could be designed to test the relationship between barriers 
and adherence (not available in the present data set), the separate association of 
adherence and barriers with demographic factors and CVD outcome is postulated to be 
evidence for the inverse relationship between adherence and barriers. Demographic 
factors of patients influence both the barriers and medication adherence, and possibly 
modify each other in their association with the two hidden constructs. Advised by this 
conceptual framework, this dissertation proposes to assess patients’ perceived barriers to 
medication use as proxy to medication adherence.  
Accordingly, this dissertation pursued three related objectives: i) to develop and 
psychometrically evaluate a self-administered scale designed to assess patients’ 
perception of barriers to using medication as prescribed, the Murage-Marrero-Monahan 
Medications barrier scale (4M scale). ii) to determine whether patients’ age, gender, 
race/ethnicity, education and household income are associated with specific barriers to 
using medication as prescribed. iii) to assess the association between patients’ perceived 
barriers to medication use and cardiovascular disease risk. 
5 
The first step was to develop a valid and reliable instrument that can assess the 
latent construct of patients’ perceived barriers to using medication as prescribed by their 
healthcare provider from the patients’ explicit external experiences and their perceived 
frequency of barriers. Then to determine what specific demographic factors are 
associated with identified barriers. This information would facilitate interpretation and 
practical application of the tool in routine clinical care. Finally, the identified barriers 
were examined for association with CVD risk control, an intermediate stage leading to 
CVD, an outcome experienced by most diabetes patients. 
 
 
 
  
Figure 1.1 Conceptual Framework of Patient Perceived Barriers to Using Medications as Prescribed by their Healthcare 
Provider. 
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1.2 Development and psychometric evaluation of the Murage-Marrero-Monahan 
Medication Barriers scale (4M Scale) 
While medication adherence has been attributed to less than optimal treatment 
outcomes among diabetes patients in spite of availability to treatments with known 
efficacy, current methods of assessing medication adherence are limited by cost, accuracy 
and feasibility. Even self-reported measures, despite having good validity and reliability, 
are often influenced by social desirability bias, limiting their accuracy. Therefore, this 
study seeks to develop a self-reported tool that indirectly assesses barriers and their 
frequencies as proxies to identifying issues with medication adherence. The study further 
evaluates psychometric properties of the instrument. 
 
1.3 Patient demographic characteristics associated with barriers to using 
medications as prescribed 
To help identify patients who may need additional adherence support, previous 
studies have focused on identifying patient characteristics associated with medication 
adherence. These studies have provided important insight on patient medication 
adherence traits but have failed to identify specific problems that can be targeted by 
adherence interventions, hence diminishing the likelihood of any interventions 
succeeding. Therefore, this study aimed to determine whether specific demographic 
characteristics are associated with barriers to using medications as prescribed. The 
purpose was to enhance interpretation of the developed scale and to allow care providers 
to structure personalized interventions to address the identified barriers, increasing the 
likelihood of interventions succeeding. 
8 
 
1.4 Patient perceived barriers to medication use and cardiovascular disease risk 
Most people with diabetes continue to progress to full blown CVD, despite availability of 
treatments to control CVD risk factors. Again, this observation is attributed to medication 
adherence. This study sought to determine whether barriers are associated with CVD risk 
control, an intermediate step to CVD.  An association, if found, would establish the 
importance of considering barriers in routine care of patients with diabetes and point 
toward specific interventions. By extension, these findings will provide evidence on 
whether barriers can indicate issues with medication adherence that would lead to similar 
consequences. 
 This dissertation is organized as follows: chapter 2 presents development and 
psychometric evaluation of the self-administered Murage-Marrero-Monahan Medication 
Barrier scale. Chapter 3 presents a study examining whether patient demographic factors 
are associated with barriers to using medications as prescribed. Chapter 4 presents the 
study determining whether patient perceived barriers to medication use are associated 
with poor control of cardiovascular risk factors. Finally, Chapter 5 provides an overall 
discussion and concluding remarks. 
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CHAPTER 2 
 
DEVELOPMENT AND PSYCHOMETRIC EVALUATION OF THE MURAGE- 
MARRERO-MONAHAN MEDICATION BARRIERS SCALE (4M SCALE) 
 
2.1 Abstract 
Purpose 
To develop and evaluate psychometric properties of the Murage-Marrero-
Monahan Medication Barriers scale (4M scale), a tool for assessing patients’ perceived 
barriers to taking medications as prescribed, as an alternate to assessing medication 
adherence. 
Methods 
Scale items were generated from literature review and 12 focus groups of diabetes 
patients. A cross-sectional study of diabetes patients yielded 362 surveys from 1,000 
mailed surveys of the 4M scale. 
Results 
Analysis focused on 343 respondents with Type 2 diabetes. Mean age was 59, 
mean age at diagnosis 48, and mean diabetes duration 11 years. Most were female (72%) 
and African American (52%).  Therapies included oral antihyperglycemic agents (OHA) 
(51%), insulin (18%), and combined OHA and insulin (28%). The initial 20 items were 
reduced to 19 items with valid psychometric properties as either a five-domain or a 
single-domain structure. The five domains were poor communication with providers, 
poor understanding of and/or difficulty using medicine, poor personal access, side effects 
10 
and system barriers. For the five-domain structure, factor loadings ranged from 0.37 to 
0.69 (median 0.58) (single domain, 0.42 to 0.81; median 0.61), coefficient alpha ranged 
from 0.70 to 0.83 (single domain, 0.92). As evidence of validity, both structures had low 
and inverse correlations with quality of life measures, and revealed lower barrier 
experiences among patients on OHA than those on insulin or OHA plus insulin.  
Conclusion  
The 4M scale demonstrated acceptable validity and reliability both as a five-
domain and single-domain instrument among patients with Type 2 diabetes from a low 
income population. 
 
Keywords for indexing 
Diabetes, Medication barriers, Psychometric, Validity, Reliability 
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2.2 Introduction 
The burden of diabetes is reaching epidemic levels with estimates suggesting that 
the incidence will increase to 35% of the U.S. population by 2050 (1). In 2012, more than 
29 million people in the US had diabetes and an additional 89 million had pre-diabetes 
that significantly increases their risk for developing the disease. The burden of this 
disease has significant social and fiscal impacts (2, 3). In 2012, a total fiscal burden of 
$245 billion was attributed to diabetes, a 41% increase from 2007 (4, 5). The social and 
psychological costs are incalculable (4). 
Efforts to reduce this burden have focused on preventive measures, early 
diagnosis and more aggressive diabetes management (5). In spite of a wide array of 
effective treatment options, however, many persons with diabetes are still not achieving 
optimal therapeutic outcomes (6-14). Medication adherence is increasingly implicated as 
a potential explanation for this discrepancy (10, 12). The World Health Organization 
(WHO) defines adherence as “the extent to which a person’s behavior – taking 
medication, following a diet and/or executing lifestyle changes, corresponds with agreed 
recommendations from a health care provider” (36). 
Research illuminates the importance of medication adherence, particularly among 
persons with diabetes. Several studies have shown that poor adherence is associated with 
poor glycemic control, and increased risk of cardiovascular complications, whereas 
higher medication adherence is linked to better glycemic control, improved health 
outcomes, lower healthcare utilization and lower healthcare costs (10, 23-28). For 
example, good medication adherence has been associated with improved glycemic 
control and greater weight loss (37, 38). Additional evidence has demonstrated that 
12 
medication adherence is a modifiable behavior that can be improved with appropriate 
intervention once poor adherence is identified (29). Unfortunately, many patients with 
diabetes do not report taking their medications as prescribed by their health care 
providers (22, 39). 
There is currently no “gold standard” for assessing medication adherence and 
each method has limitations. Biological measures are costly and often refused by study 
participants (32, 33). Pill counts and drug possession measures are often inaccurate (31). 
Self-reported measures have many benefits, especially simplicity, low cost and accuracy 
that can be improved  by developing scales with adequate validity and reliability (34). 
Existing self-report measures, however, are subject to reporting errors arising from social 
desirability bias; the tendency to report adherence when directly confronted by providers 
about a specific medication. 
Therefore, our goal was to develop and evaluate psychometric properties of a self-
administered scale designed to indicate adherence issues while avoiding direct 
confrontation by assessing respondents’ perceptions of barriers experienced in using any 
medications as prescribed, and not tied to their immediate utilization. We postulate that 
this approach would lessen patient reactance to being directly confronted about their 
medication use and allow them to suggest areas that may be addressed during clinical 
encounters (40). Also, when coupled with biomarkers that suggest response to therapy, 
the reporting of “generalized” barriers may indicate current adherence issues. In this 
regard, this approach will serve as an indicator of medication adherence. In addition, 
defining barriers could facilitate discussion between the patient and provider when a 
13 
barrier is identified and coupled with other data suggesting poor adherence. We titled this 
instrument the Murage-Marrero-Monahan Medication Barriers (4M) scale. 
 
2.3 Methods 
2.3.1 Conceptual framework and item generation 
The concept barriers was defined as patients’ perceived obstacles to using 
medication as prescribed by a healthcare provider. 
Item generation was a process that involved literature review and focus groups. 
Key concepts surrounding diabetes medication were identified from literature. The 
concepts were then used to guide focus group exercises. A series of twelve (12) focus 
groups led by trained facilitators were used to identify central themes. The 6 all-female 
and 6 all-male focus groups consisted of a diverse population of 121 adult patients with 
Type 1 or Type 2 diabetes: 73(60%) were female, 92(76%) were at least 50 years old, 
71(59%) were Caucasians, and 50(41%) were African Americans. Participants in each 
focus group first discussed perceived barriers freely, and then further discussions were 
probed using concepts from the literature that had not been addressed. Themes were 
derived from printed transcripts reviewed by three independent raters. 
A pool of 20 items was generated from six themes that emerged from the focus 
groups: six access and acceptability items (1, 2, 3, 15, 17 and 18), two knowledge and 
understanding items (4 and 5), four beliefs items (6, 9, 19 and 20), one cost item (14), 
four side effects items (7, 8, 10 and 11) and three memory items (12, 13 and 16). To 
improve understandability and readability, the items incorporated language from focus 
group participants.  
14 
 
2.3.2 Content validity 
Content validity was assessed through clinical experts and a pilot test. In-person 
discussions with 6 clinical experts provided additional consensus on comprehensiveness 
of the items and affirmed their relation to the overall concept. Additionally, the pilot test 
conducted on a convenience sample of 28 patients with diabetes revealed acceptable 
interpretability and understandability of the items. Hence, all 20 items were retained as 
assessing barriers to medication use. 
 
2.3.3 Survey population 
A cross sectional study design was used to assess psychometric properties of the 
instrument. An indigent inner-city population in Indianapolis was deliberately targeted 
because it was expected to have a disproportionate burden of diabetes by prevalence (41), 
high use of polypharmacy (42), social and fiscal costs (43), diabetes related poor health 
outcomes (44), and lower medication adherence (45). Approval was obtained from the 
Indiana University-Purdue University Indianapolis, Institutional Review Board. The 
study survey administration and study participants are described in detail elsewhere (46). 
 
2.3.4 Survey 
In addition to responses on the 20 items of the 4M scale, the survey also obtained 
information on age, education, gender, race, marital status, whether living with a spouse, 
number of household occupants, household income, type of diabetes, age at diagnosis and 
current diabetes medications. Responses on type of diabetes were corrected for patients 
15 
who were unsure of their diabetes type (62 patients), or did not provide a response on the 
type of diabetes (9 patients), or provided a response inconsistent with age at diagnosis or 
insulin use. The correction was based on synthesis of the type of diabetes provided (if 
any) and survey responses on insulin use, age at diagnosis and current age. 
All 20 items of the 4M scale assessed patients’ perceived barriers to medication 
use as prescribed. The stem for all items read, “Sometimes people do not take their 
medications as prescribed by their doctor. There are many reasons why this can happen. 
Have you ever experienced any of the reasons listed below, and if so, how often?” Each 
item score ranged from 1 to 5 on a five-category frequency response scale: “Never”, 
“Rarely”, “Sometimes”, “Often” and “Very Often”, respectively.  
Subscale scores were obtained by adding responses of all items under their 
respective 4M subscale, whereas the overall score was obtained by summation of 
responses from all 20 items. Because missing responses per item was minimal (highest 
8%), subscale scores were not imputed. Lower subscale and overall scores indicated less 
experience with a specific barrier to medication use. 
 
2.3.5 Statistical analysis 
Scale formation and item reduction 
Exploratory factor analysis (EFA) and conceptual relevance of rotated factors 
were used to determine number of factor and items to retain (47). To retain an item, it had 
to achieve a rotated factor loading of 0.40 or greater (0.30 or more was acceptable if an 
item demonstrated compelling conceptual relevance), be conceptually relevant, and have 
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a corrected item-total correlation of 0.30 or greater (48). All analyses were performed 
using SAS software (Version 9.4, SAS Institute, Cary, NC). 
Data quality and descriptive statistics 
Data quality was examined through item variability and data completeness. Item 
variability was assessed by item response frequency distributions, means, standard 
deviations, floor effects and ceiling effects. Completeness of data was evaluated by 
calculating the percentage of missing data for each item. 
Descriptive characteristics of perceived barriers measured by the 4M instrument 
were estimated by calculating scale score means, medians, standard deviations, range, 
ceiling effects, and floor effects. Data completeness was evaluated by the proportion of 
participants whose scale scores were not calculable. A cut-off of more than 15% in the 
best or worst possible score was evidence of ceiling or floor effects for scale scores (26, 
49, 50). 
Factor analysis and item-convergent-discriminant validity 
Exploratory factor analysis (EFA) and a scree plot were used to determine the 
number of factors to extract (47). The principal component method was used for 
estimating parameters, and squared multiple correlations was used for the initial 
communalities. After specifying the number of factors to retain, Varimax rotated factor 
loadings and conceptual relevance were used to attribute items to respective factors. 
Corrected item-total correlations for each item – corrected to exclude the item from the 
total score – were calculated to assess item-convergent validity (51). A corrected item-
total correlation greater than or equal to 0.3 was considered acceptable item contribution 
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to its respective scale score (48). Item-discriminant validity was examined by correlating 
each item with subscales to which it was not assigned. 
Reliability 
Cronbach’s coefficient alpha was used to evaluate internal consistency reliability 
(50, 51). A coefficient alpha of 0.7 or above was considered acceptable internal 
consistency reliability for group comparisons (48, 50). 
Discriminant validity 
Discriminant validity was examined by correlating the extracted factors 
(subscales and total score) with four generic quality of life (QoL) measures: SF-36 single 
item general health, SF-36 mental health, SF-36 vitality and Rand health distress 
measures (52, 53). It was hypothesized the scale factors will correlate significantly, lowly 
and inversely with all four QoL measures. Small significant negative correlations were 
expected because medication non-adherence (presumably in part from increased 
perceived barriers) is expected to lead to poor general and mental health, inactivity and 
stress. The magnitude of correlation was expected to be small because many personal and 
environmental variables can impact quality of life. 
Known-group validity 
Known-group validity was evaluated by comparing 4M scale median scores 
(subscale and overall total) to three medication regimens: oral antihyperglycemic agents 
(OHA) therapy only, insulin therapy only, and insulin plus OHA combined therapy. 
Previous studies have shown adherence rates are lower for insulin therapy than OHA 
therapy and lower for polypharmacy regimens than monotherapy regimen (6). Therefore, 
for each 4M scale score, we hypothesized patients on combined therapy (OHA plus 
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insulin) will have the highest median scores on perceived barrier scale scores, then those 
on insulin monotherapy the next highest and finally those on OHA with the lowest barrier 
scale scores. The Kruskal-Wallis test was used to test differences between the calculated 
medians for each subscale. The Wilcoxon rank sum test was used for further pairwise 
comparisons of the three possible pairs of medication regimens. Similar tests were 
repeated for the overall 4M scale total score.  
 
2.4 Results 
2.4.1 Sample characteristics 
A response rate of 36% (362) was realized from 1,000 questionnaires sent to the 
target population. As reported by Monahan et al. non-responders did not differ by age or 
race to responders, but were more likely to be male (46). 
Patients with Type 1 diabetes were excluded in subsequent analyses because most 
of the participants had Type 2 diabetes, 95% (343) of survey respondents. Subsequently, 
further development of the 4M scale focused on patients with Type 2 diabetes. 
Demographic and therapy traits of the responding 343 Type 2 diabetes patients 
are provided in Table 2.1. Mostly they were females with low income levels, non-
Hispanic African Americans, and over half were on OHA only. Nine respondents 
reported not taking any medication but were included in the study and considered 
currently non-adherent because their responses indicated experience with medication.  
Scale formation and item reduction  
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Table 2.1 Study population characteristics   
Characteristics (n = 343) Mean (SD) Median (Range) 
Current age [years] 59.4 (11.3)  59.0 (24-95) 
Age when diagnosed with diabetes 47.7 (12.8) 48.5 (6-95) 
Highest year of education completed 11.0 (2.4) 12.0 (2-17) 
Duration with diabetes since diagnosis [years] 11.4 (11.0)  8.0 (0-68) 
Characteristics Number (%) 
Gender  
Female 247 (72) 
Male 93 (27) 
Unidentified 3 (1) 
Race  
Non-Hispanic African American 178 (52) 
Non-Hispanic Caucasian 141 (41) 
Hispanic / Latino 3 (1) 
Other races 11 (3) 
Unidentified 10 (3) 
Marital status  
Never married 72 (21) 
Married 92 (27) 
Divorced 77 (22) 
Separated 16 (5) 
Widowed 83 (24) 
Unidentified 3 (1) 
Living with a spouse or significant other  
Yes 139 (41) 
No 200 (58) 
Unidentified 4 (1) 
Number of people living in Household (including participant) 
One 117 (34) 
Two 120 (35) 
Three 44 (13) 
Four 28 (8) 
Five or more 30 (9) 
Unidentified 4 (1) 
Total Household Income (before taxes)  
Less than or equal to $15,000 250 (73) 
$15,001 to $30,000 55 (16) 
$30,001 to $45,000 12 (4) 
$45,001 to $100,000 8 (2) 
Unidentified 18 (5) 
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Table 2.1 continued. 
Characteristics Number (%) 
Type of diabetes medication therapy  
No Medication 9 (3) 
One oral antihyperglycemic agent  (OHA)  93 (27) 
Two or more OHA 83 (24) 
Insulin only 62 (18) 
Combined Insulin and OHA  95 (28) 
Unidentified 1 (0) 
Insulin administration method  
Syringe 141 (90) 
Insulin pen 10 (6) 
Insulin pump 1 (1) 
Syringe and insulin pen 2 (1) 
Unidentified 3 (2) 
Insulin injections per day  
One time 21 (13) 
Two times 124 (79) 
Three or more times 11 (7) 
Unidentified 1 (1) 
Number of OHAs taken  
One kind 24 (40) 
Two kinds 18 (30) 
Three or more kinds 7 (12) 
Unidentified 11 (18) 
Number of times OHA taken per day  
One time a day 10 (17) 
Two times a day 32 (53) 
Three or more times a day 5 (8) 
Unidentified 13 (22) 
 
n = total number of participants. SD=Standard deviation. OHA = Oral Antihyperglycemic 
Agents. Means and medians are rounded to the nearest one decimal place; all percentages 
are rounded to the nearest whole number. 
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Exploratory factor analysis (EFA) and conceptual relevance was used to reduce 
the initial 20 items to 19 items and five identified factors. The same criteria were used to 
evaluate a one-factor solution. EFA on all 20 items revealed poor loadings (less than 
0.36) for item 19 (“I just don’t like taking medicine in general”) on all five potential 
factors. The item was dropped and subsequent scale development focused on the 19 items 
retained (Table 2.2).  
 
2.4.2 Data quality and descriptive statistics 
Item response rates and item distributions were satisfactory (Table 2.2). Although 
item response scores were skewed, in which most participants responded with favorable 
“never” regarding experience with the barriers, respondents used all response categories 
for all items. Item means ranged from 1.2 to 2.3 (median 1.7) and standard deviation 
from 0.7 to 1.4 (median 1.0). With the exception of item 4 (“I don’t know what doses to 
take”), which had the highest ceiling effect (86% of participants responding “Never”), the 
percentage of “never” responses for all other items ranged from 44% to 74% (median 
60%). Floor effects were below 13%. Rates of missing responses per item ranged from 
5% to 8% (median 6%). Item 6 (“I don’t feel my medicines are helping me”) had the 
highest missing response rate (8%). 
 
 
 
 
 
 Table 2.2 Distributions and missing rates for all 20-items 
Item 
Item 
Mean 
Item 
SD 
Response scale counts % 
Missing 1 2 3 4 5 
a
1 The pharmacy could not refill my prescription. 1.6 1.0 222 49 36 7 10 6 
a
2 My doctor or nurse forgot to write a new prescription for my 
medicine. 
1.5 0.9 227 53 31 6 5 6 
a
3 I had to cancel or put off a visit to my doctor or nurse and ran 
out to medicine. 
1.7 1.0 183 67 58 3 9 7 
b4 I don’t know what dose to take. 1.2 0.7 273 24 13 5 3 7 
b
5 I am not sure exactly what each medicine is for. 1.5 1.1 237 34 26 6 18 6 
c6 I don’t feel my medicines are helping me. 1.8 1.2 191 35 64 13 14 8 
e
7 They are unpleasant to take (e.g. hard to swallow, bad tasting, 
painful). 
1.6 1.0 220 41 38 12 9 7 
e
8 My medicines make me feel bad or have side effects that I 
don’t like. 
1.7 1.1 192 54 47 15 11 7 
c
9 I have heard about side effects that I am afraid I might get. 1.7 1.1 192 52 54 12 9 7 
e10 It’s too had to keep track of what I am supposed to take 
when. 
1.5 0.9 221 46 38 10 4 7 
e
11 There are too many doses to take each day. 1.6 0.9 206 55 45 11 4 6 
f
12 I just forget to take them. 1.9 1.0 162 73 63 14 8 6 
f
13 I forget to refill my prescription in time. 1.7 0.9 181 76 53 10 4 6 
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 Table 2.2 continued. 
Item 
Item 
Mean 
Item 
SD 
Response scale counts % 
Missing 1 2 3 4 5 
d14 I can’t afford them. 2.2 1.4 141 49 80 14 36 7 
f
16 I sometimes forget to ask my doctor or nurse about problems 
that I am having with my medicines. 
1.9 1.1 171 49 84 13 8 5 
a
17 I sometimes find it hard to ask my doctor or nurse questions 
about my medicines. 
1.6 1.0 215 41 50 8 10 6 
a
18 Getting to the pharmacy to pick up my medications is difficult. 2.3 1.4 146 37 87 22 32 6 
c19 I just don’t like taking medicine in general. 2.2 1.4 145 48 75 15 39 6 
c
20 Taking medicines means my health will get worse. 1.5 0.9 225 48 37 7 5 6 
 
All items had a five-response scale: 1 = Never, 2 = Rarely, 3 = Sometimes, 4 = Often, and 5 = Very often. % Missing = 
percentage of participants with a missing response on the respective item. Item SD = Item standard deviation. The number 
before each item statement is arbitrary and simply identifies each barrier item number for the study. The stem for all items 
read, “Sometimes people do not take their medications as prescribed by their doctor. There are many reasons why this can 
happen. Have you ever experienced any of the reasons listed below, and if so, how often?” 
a
 Generated from access and acceptability theme. 
b
 Generated from knowledge and understanding theme. 
c 
Generated from beliefs theme. 
d
 Generated from cost theme. 
e
 Generated from side effects theme. 
f
 Generated from memory theme. 
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2.4.3 Factor analysis and item-convergent-discriminant validity 
Five factors were retained after examining the scree plot (Figure 2.1) and rotated 
factor loadings (Table 2.3). The five factors explained 100% of the shared variance and 
53% of the total variance from 19 items. The one-factor solution was also considered 
because although it explained only 39% (7.46) of the total variance, it explained 79% of 
the shared variance, it has conceptual relevance as a single total barrier score, all its 
loadings exceeded 0.40, and importantly, the scree plot indicated one dominant 
dimension. 
 
 
Figure 2.1 Scree plot displaying number of factors against eigenvalues from the 
exploratory factor analysis using squared multiple correlations as initial communalities. 
 
Factor loadings and item total correlations on the five retained factors were 
estimated (Table 2.3). Except for item 6 (“I don’t feel my medicines are helping me”), all 
other items loaded highly (≥0.41) to one of the factors. The highest loading for item 6 
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was slightly below 0.40 (0.37) on factor 1 and factor 4, but was retained under factor 4 
because of its conceptual relevance. Except for the case of item 6, all items loaded lower 
with other factors than their assigned factor.  
Corrected item-total correlations between each item and its own assigned total 
subscale score revealed strong (r≥0.46) item-convergent validity (Table 2.3).  All 
nineteen items correlated lower with the other four subscales (range 0.20 to 0.63; median 
0.44) exhibiting acceptable item-discriminant validity. 
 
 
 Table 2.3 Rotated Factor Loadings – Five-factor solution 
Item 
Rotated Factor Loadings 
r Sub-scale Naming 
F1 F2 F3 F4 F5 
15 I don’t have enough time to talk with my doctor or nurse about 
problems that I’m having with my medicines. 
.62 .28 .26 .25 .23 .68 
F1 Poor 
communication with 
providers 16 I sometimes forget to ask my doctor or nurse about problems 
that I am having with my medicines. 
.66 .41 .31 .22 .14 .77 
17 I sometimes find it hard to ask my doctor or nurse questions 
about my medicines. 
.66 .26 .29 .12 .25 .69 
20 Taking medicines means my health will get work. .52 -.8 .11 .28 .11 .48 
4 I don’t know what dose to take. .8 .52 .6 .13 .37 .49 
F2 Poor 
understanding and/or 
difficulty using 
medicine 5 I am not sure exactly what each medicine is for. .17 .54 .9 .12 .24 .52 
10 It’s too had to keep track of what I am supposed to take when. .15 .64 .36 .26 .13 .61 
11 There are too many doses to take each day. .13 .57 .35 .26 .11 .61 
12 I just forget to take them. .15 .31 .65 .12 .5 .53 
F3 Poor personal 
access 
13 I forget to refill my prescription in time. .24 .16 .69 .15 .19 .62 
14 I can’t afford them. .23 .7 .48 .26 .20 .51 
18 Getting to the pharmacy to pick up my medications is difficult. .37 .23 .41 .13 .20 .52 
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 Table 2.3 continued 
Item 
Rotated Factor Loadings 
r Sub-scale Naming 
F1 F2 F3 F4 F5 
12 I just forget to take them. .15 .31 .65 .12 .5 .53 
F3 Poor personal 
access 
13 I forget to refill my prescription in time. .24 .16 .69 .15 .19 .62 
14 I can’t afford them. .23 .7 .48 .26 .20 .51 
18 Getting to the pharmacy to pick up my medications is difficult. .37 .23 .41 .13 .20 .52 
6 I don’t feel my medicines are helping me. .37 .31 .26 .37 .17 .57 
F4 Side effects 
7 They are unpleasant to take (e.g. hard to swallow, bad tasking, 
painful). 
.19 .35 .15 .47 .24 .58 
8 My medicines make me feel bad or have side effects that I don’t 
like. 
.27 .26 .31 .61 .13 .73 
9 I have heard about side effects that I am afraid I might get. .36 .26 .16 .59 .9 .63 
1 The pharmacy could not refill my prescription. .10 .26 .15 .14 .60 .54 
F5 System barriers 
to access 
2 My doctor or nurse forgot to write a new prescription for my 
medicine. 
.24 .24 .12 .6 .58 .57 
3 I had to cancel or put off a visit to my doctor or nurse and ran 
out to medicine. 
.21 .3 .42 .16 .47 .46 
 
Rotated factor loadings with items rearranged by the factors on which they load highest or to which they are assigned. r = 
corrected item-total correlation between an item and its subscale total, excluding the item from the total score. This factor 
analysis was based on a sample size of 286 participants (57 participants had missing data on one or several of the 19 retained 
items). Factor loadings of the items and their assigned factors are in bold. Sub-scales naming provides interpretations of the 
factors (F1to F5) based on the bolded item loadings under the factor. The five factors explain all of the shared variance and 
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53% of the total variance from 19 items. Item 19 “I just don’t like taking medicine in 
general” was dropped after initial exploratory factor analysis due to poor loadings on all 
five potential factors. 
 
Similar analyses were repeated with the one-factor solution (Table 2.4). Item 
loadings ranged from 0.42 to 0.81 (median 0.61) and corrected item- total correlations 
ranged from 0.40 to 0.77 (median 0.59) for a single domain scale score.  
Based on the items assigned to a factor on the five-factor solution, the factors and 
their corresponding subscale scores were interpreted and named as follows: factor 1 (F1) 
Poor communication with providers, factor 2 (F2) Poor understanding of and/or difficulty 
using medicine, factor 3 (F3) Poor personal access, factor 3 (F4) Side effects and factor 5 
(F5) System barriers to access. The single factor from the one-factor solution was named 
the overall single-factor 4M scale. 
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Table 2.4 Factor Loadings – One factor solution (Overall single-factor 4M scale) 
Item 
One Factor 
Loadings 
r 
1 The pharmacy could not refill my prescription. .52 .49 
2 My doctor or nurse forgot to write a new prescription for 
my medicine. 
.53 .50 
3 I had to cancel or put off a visit to my doctor or nurse 
and ran out to medicine. 
.55 .53 
4 I don’t know what does to take. .51 .48 
5 I am not sure exactly what each medicine is for. .52 .49 
6 I don’t feel my medicines are helping me. .67 .64 
7 They are unpleasant to take (e.g. hard to swallow, bad 
tasking, painful). 
.61 .58 
8 My medicines make me feel bad or have side effects that 
I don’t like. 
.70 .67 
9 I have heard about side effects that I am afraid I might 
get. 
.65 .62 
10 It’s too had to keep track of what I am supposed to take 
when. 
.71 .66 
11 There are too many doses to take each day. .66 .63 
12 I just forget to take them. .60 .56 
13 I forget to refill my prescription in time. .66 .63 
14 I can’t afford them. .55 .54 
15 I don’t have enough time to talk with my doctor or 
nurse about problems that I’m having with my 
medicines. 
.75 .72 
16 I sometimes forget to ask my doctor or nurse about 
problems that I am having with my medicines. 
.81 .77 
17 I sometimes find it hard to ask my doctor or nurse 
questions about my medicines. 
.73 .70 
18 Getting to the pharmacy to pick up my medications is 
difficult. 
.61 .59 
20 Taking medicines means my health will get work. .42 .40 
 
r = corrected item-total correlation between an item and its subscale, excluding the item 
from the total score. This factor analysis was based on a sample size of 286 participants 
(57 participants had missing data on one or several of the 19 retained items). The single-
factor explains 79% (7.46) of the shared variance (9.41) and 39% of the total variance 
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from 19 items. Item 19 “I just don’t like taking medicine in general” was dropped after 
initial exploratory factor analysis due to poor loadings on all five potential factors. 
 
2.4.4 Reliability  
Cronbach’s alpha is reported in Table 2.5. Cronbach’s coefficient alpha for the 
five-factors and single-factor solutions were acceptable (α ≥ 0.70) (54). 
 
Table 2.5 Reliability  
Five-factor 4M subscales and Overall single-factor 4M 
Scale 
Cronbach’s  
coefficient alpha 
F1 Poor communication with providers .83 
F2 Poor understanding and/or difficulty using medicine .75 
F3 Poor personal access .74 
F4 Side effects .81 
F5 System barriers to access .70 
Overall single-factor 4M scale .92 
 
F1, F2, F3, F4 and F5 are arbitrary identifiers of the factor number for the 5-factor 
subscales. 4M scale = Murage-Marrero-Monahan Medication Barriers scale. 
 
2.4.5 Features of scale score distributions 
The subscale means (standard deviations) ranged from 4.7 to 8.0 (2.2 to 3.5) 
indicating lower experiences with the barriers and acceptable variability (Table 2.6). 
Whereas floor effects were unnoticeably small (<1%), ceiling effects ranged from 24% to 
55%. The proportion of subscale scores not computable ranged from 7% to 11%. 
Observed scores for the overall single-factor 4M scale ranged from 19 to 87. The 
scores were adequately variable with a mean score of 32 (standard deviation 12.4) and 
median of 30. A ceiling effect of 18% and a negligible floor effect were observed. 
Seventeen percent of total scores could not be computed. 
 Table 2.6 Descriptive features of the five-factor 4M subscales and overall single-factor 4M scale 
4M Subscales and Overall 
single-factor 4M Scale 
Number 
of items 
Possible 
Range 
Observed 
Range 
Mean Median SD 
% 
Ceiling 
% 
Floor 
% 
missing 
F1 Poor communication with 
providers 
4 4-20 4-20 6.7 5.0 3.3 40.8 0.3 7 
F2 Poor understanding and/or 
difficulty using medicine 
4 4-20 4-20 5.9 4.0 2.8 52.8 0.3 10 
F3 Poor personal access 4 4-20 4-20 8.0 8.0 3.5 23.9 0.6 8 
F4 Side effects 4 4-20 4-20 6.9 6.0 3.4 40.8 0.7 11 
F5 System barriers to access 3 3-15 3-15 4.7 4.0 2.2 45.7 0.6 9 
Overall single-factor 4M scale 19 19-95 19-87 32.0 30.0 12.4 18.2 0 17 
 
SD = standard deviation. 4M scale = Murage-Marrero-Monahan Medication Barriers scale. % Ceiling is the proportion of 
respondents per factor (or subscale) responding favorably i.e. minimum score. % floor is the proportion of respondents per 
factor (or subscale) responding unfavorably i.e. maximum score. % missing is the proportion of scores not calculable per factor 
(or subscale). 
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2.4.6 Scale to scale correlations 
Inter-scale correlations between the five subscale scores were moderate in 
magnitude, ranging from 0.46 to 0.68 (median 0.56; p<0.0001 all correlations) (Table 
2.7). The moderate correlations indicated that the subscales measured related but 
distinctly different domains of perceived barriers to medication use.  
 
Table 2.7 Subscales correlations     
4M Subscales 4M Subscales 
 F1  F2  F3  F4  
F1 Poor communication with providers      
F2 Poor understanding and/or difficulty using 
medicine 
0.57    
F3 Poor personal access 0.61 0.55   
F4 Side effects 0.68 0.62 0.59  
F5 System barriers to access 0.51 0.47 0.52 0.46 
 
Pearson correlation was used to compute the correlations. 4M scale = Murage-Marrero-
Monahan Medication Barriers scale. F1-F5 = factors. 
 
2.4.7 Discriminant validity 
Correlations of the five subscale scores and overall 4M total score with the four 
QoL measures displayed evidence of discriminant validity (Table 2.8). Pearson 
correlations between the QoL measures – SF-36 single item general health, SF-36 mental 
health, SF-36 vitality and Rand health distress scales – and the five subscales ranged 
from -0.45 to -0.11 (median -0.27). Except for the correlation between Vitality QoL and 
F5 “system barriers to access” (p=0.055) which was marginally significant, all other 
correlations were significant (p<0.05). Correlations of the overall single-factor 4M scale 
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score with the same QoL measures presented similar results: (range -0.25 to -0.43; 
median -0.37; all p<0.0001). The strongest correlations with QoL measures were 
observed for poor personal access and the total 4M barriers scale.  
 
Table 2.8 Pearson correlation of the five-factor 4M subscales and overall single-factor 
4M scale to QoL measures 
Five-factor 4M Subscales and 
Overall single-factor 4M Scale 
SF36 single 
item general 
health 
SF-36 
Mental 
health 
SF-36 
Vitality 
Rand 
Health 
Distress 
F1 Poor communication with 
providers  
-.23 -.29 -.16 -.35 
F2 Poor understanding and/or 
difficulty using medicine  
-.20 -.26 -.13 -.28 
F3 Poor personal access  -.30 -.45 -.27 -.41 
F4 Side effects -.20 -.35 -.21 -.35 
F5 System barriers to access -.13 -.19 -.11 -.22 
Overall single-factor 4M scale -.31 -.43 -.25 -.43 
 
QoL = Quality of life. 4M scale = Murage-Marrero-Monahan Medication Barriers scale. 
All correlations were significant at p<0.05, except between Vitality QoL measure and F5 
System barriers to access subscale (P=0.0545) which was marginally significant. All 
correlations are Pearson correlation coefficients. 
 
2.4.8 Known-group validity 
Median scores of the five subscales across the three medication regimens ranged 
from 3 to 8 (Table 2.9). Kruskal-Wallis tests comparing the three medication regimens 
(OHA alone, Insulin alone and OHA plus Insulin combined) revealed significant 
differences in median scores across three subscales: F2 “poor understanding of and/or 
difficulty using medicine”, F4 “side effects”, and F5 “system barriers to access”.  
Subsequent pairwise comparisons of their medication regimen median scores revealed 
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that OHA therapy alone was significantly different than insulin therapy alone, and also 
significantly different than OHA plus insulin combined therapy. OHA therapy alone had 
significantly lower median scores than the other two therapies. A similar pattern was 
observed on the median score of the overall single-factor 4M scale. Specifically, OHA 
therapy alone had significantly lower median score (26.0) than the other two therapies 
(31.5 and 32.0). 
 
 
 
 Table 2.9 Known-groups medication discriminant validity 
Five-Factor 4M Subscales and 
Overall Single-Factor 4M 
Scale 
Diabetes medication 
therapy 
Overall 
comparison 
(𝝌𝟐)a 
Pairwise comparisons
b
 
OHA 
alone 
(n=176) 
Insulin 
alone 
(n=62) 
OHA + 
Insulin 
(n=95) 
OHA 
alone vs. 
OHA + 
Insulin 
Insulin 
alone vs. 
OHA + 
Insulin 
OHA alone 
vs. Insulin 
alone 
F1 Poor communication with 
providers 
5.0 5.0 6.0 2.27 12,521 5,876 9,321 
F2 Poor understanding of and/or 
difficulty using medicine 
4.0 6.0 6.0 11.60** 12, 646** 5,891 9,659** 
F3 Poor personal access 7.0 8.0 8.0 4.04 12,280 5,811 9,468 
F4 Side effects 5.0 6.0 7.0 9.83** 12,134** 5,339 9,142* 
F5 System barriers to access 3.0 4.0 4.0 6.27* 12,309* 5,681 9,373* 
Overall single-factor 4M scale 26.0 31.5 32.0 9.03* 10,968** 4,539 7,768* 
 
4M scale = Murage-Marrero-Monahan Medication Barriers scale. OHA = One or more oral antihyperglycemic agents. 𝜒2 
denotes Kruskal-Wallis chi-square. Values in columns 2, 3, and 4 are median scores. Values in column 5 are Kruskal-Wallis 
chi-squares. Values in columns 6, 7, and 8 are Wilcoxon rank sum T-Statistics. N=333 respondents. The 10 respondents 
missing: one had a missing medication regimen and nine indicated that they were not using any diabetes medication. 
b
Pairwise 
comparisons by Wilcoxon rank sum test. * denotes p < 0.05, ** denotes p < 0.01. 
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2.5 Discussion 
The developed 19-item 4M scale is an adequate assessment tool for enabling 
patients to report barriers they experience to using medications as prescribed. It has 
acceptable psychometric properties – including content validity, reliability, discriminant 
validity and known-group validity – both as a five-domain instrument and as a single-
domain instrument.  
As a five-domain tool it can identify specific barriers for focused interventions, 
while as a single-domain it provides an overall assessment of barriers that can identify 
potential non-adherers. The 4M scale adequacy in assessing barriers is corroborated by its 
ability to capture all (as a five-domain) or over three-quarters (as a single-domain) of its 
items common variance, presumed as variance originating from the latent barriers to 
taking medication as prescribed. Additionally, the corrected item-total correlations 
criterion of all five domains and the single domain demonstrated acceptable item 
contribution to their respective scale (48, 55). 
The 4M scale exhibited acceptable internal consistency reliability. Cronbach’s 
coefficient alpha for the five domains (α ≥ 0.70) corroborated that each domain was 
measured with adequate internal consistency (26, 48, 50). Furthermore, removal of each 
item resulted in lower Cronbach’s alphas, except for item 20 (“Taking medicine means 
my health will get worse”). Nonetheless, the item was retained because of its conceptual 
relevance to self-reported barriers and to its domain. Cronbach’s coefficient alpha for the 
single-domain was even higher (α = 0.92), evidence that the instrument as a whole was 
internally consistent with its measurement of the common concept, patients’ perceived 
barriers to using medication as prescribed by their healthcare provider (50, 56). 
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The 4M scale revealed good discriminant validity and known-group validity both 
as a five-domain and as a single-domain instrument. In both instrument perspectives the 
instrument was correlated inversely, significantly and lowly with QoL measures 
confirming a priori hypothesis for discriminant validity. Likewise, median scores in both 
instrument perspectives revealed that patients on OHA monotherapy had lower median 
scores than those on Insulin and combined insulin and OHA therapies. This finding 
agreed with Cramer’s conclusion that medication adherence is lower for patients on 
insulin (62%) than for those on OHA  (81-85%) (57) among Type 2 diabetes patients, and 
that patients on monotherapy regimens (49%) have higher medication adherence than 
those on polypharmacy regimens (36%) (6). The results provided evidence of known-
group validity. The observed median differences were significant for three of the five 
domains and for the single domain. Absence of significance on median differences for the 
two domains, “poor personal communication with providers” and “poor personal access”, 
could be attributed to a lack of direct influence of medication regimen on the two 
domains. 
 
2.5.1 Limitations 
There are limitations to the development and generalizability of the 4M scale. 
Recall bias is possible because responses to the instrument demand recalling previous 
experiences. Second, a moderate ceiling effect was observed; however, there was no 
evidence that it affected validity or reliability perhaps because we had adequate 
variability on the response scale scores. Third, test-retest reliability data were not 
available for the barrier items. Finally, generalizability is limited by the low response rate 
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and the fact that non-responders were more likely to be male. Although the low-income 
population was ideal for this study, the population was highly transient which affected the 
response rate. Hence, findings are limited to the study population that was predominantly 
female, from low income populations, with type 2 diabetes and from Indianapolis. 
Future studies should focus on testing psychometric properties of the instrument 
in other patient populations and regions. Likewise, assessing test-retest reliability and 
criterion validity of the instrument would strengthen its purpose. Studies to explore 
potential reduction of items while maintaining reliability and validity would be beneficial 
for enhancing clinical feasibility of the instrument. Also, examining its ability to detect 
change (responsiveness to intervention) would add great value in its role as an outcome in 
medication adherence randomized controlled trials.  
 
2.6 Conclusions 
The Murage-Marrero-Monahan Medication Barriers (4M) scale provides an 
inexpensive, practical, valid and reliable alternative to assessing medication adherence 
that reduces tendencies to provide socially desirable or defensive responses to questions 
about medication use. It can be conveniently incorporated into clinical practice and 
contribute to developing medication adherence interventions.  
In addition to using the 4M subscales and overall score as outcomes in adherence 
trials, we see a potentially valuable application of the 4M scale as a tool to facilitate 
discussion between patients and their providers during clinical encounters. The 4M scale 
is easy to administer and can be easily scored to identify issues that need to be addressed. 
By identifying specific barriers, possible solutions are more likely to be generated.  
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CHAPTER 3 
 
PATIENT DEMOGRAPHIC CHARACTERISTICS ASSOCIATED WITH 
PERCEIVED BARRIERS TO USING MEDICATIONS AS PRESCRIBED 
 
3.1 Abstract 
Purpose 
To determine whether patient age, gender, race/ethnicity, education level and 
household income were associated with perceived barriers to using medications as 
prescribed. 
Methods 
A cross-sectional survey and chart audit of 964 adult, English or Spanish speaking 
patients with Type-2 diabetes (T2D) from the Translating Research into Action for 
Diabetes cohort was conducted between 2005 and 2006. Demographic factors were 
obtained and medication barriers assessed by the Murage-Marrero-Monahan Medication 
barriers scale (4M scale). Analysis of covariance (ANCOVA) was used to assess 
associations between patient demographic characteristics and identified medication 
barriers. Potential interactions of the primary demographic factors were examined with 
interaction tests. 
Results 
Age was inversely associated with all identified barriers. Household income also 
was inversely associated with two barriers: poor communication with providers and side 
effects. Gender, education level and race/ethnicity were not independently associated 
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with any barrier, but separately interacted with age and/or household income in 
influencing different barriers.  
Conclusions 
Age and household income clearly impact barriers to using medication as 
prescribed and should be considered when evaluating barriers among Type-2 diabetes 
patients. Moreover, consideration on how both variables separately interact with gender, 
education level and race/ethnicity in influencing the barriers is necessary when planning 
interventions. 
 
 Keywords  
Diabetes, Type-2 diabetes, Medication adherence, Medication barriers, Barriers, 
Demographic factors 
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3.2 Introduction 
Despite efficacy of available medication to treat diabetes and cardiovascular 
disease, expected treatment benefits often are not realized. This has been attributed, in 
part, to suboptimal medication adherence (6-14). Research also has shown that many 
patients with diabetes do not reliably take medications as prescribed (22). Additionally, 
several studies have linked the poor medication adherence to negative health outcomes, 
higher healthcare utilization and higher healthcare costs (10, 23-28, 38, 58, 59). Hence, 
the need to identify patients with poor medication adherence cannot be over emphasized, 
especially after it has been demonstrated that medication adherence is a modifiable 
behavior that can be improved with appropriate interventions targeted to patients with 
poor adherence (29). 
To help identify patients who may need additional adherence support, previous 
studies have focused on identifying personal characteristics associated with medication 
adherence. The studies have provided important insight on patient medication adherence 
traits but have failed to identify specific intervention target areas that can improve 
adherence (60, 61). Hence, the likelihood of success with interventions is greatly 
diminished.  
We suggest barriers, defined as patients’ perceived barriers to using medication as 
prescribed by their healthcare providers, can identify possible issues in medication 
adherence. In this context, understanding of patient demographic characteristics 
associated with the perceived barriers can provide insight on how demographic 
characteristics relate to specific barriers. This will facilitate care providers to structure 
personalized interventions of the barriers to improve medication adherence. Therefore, 
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this study seeks to determine whether patient age, gender, race/ethnicity, education level 
and household income, are associated with barriers to using medication as prescribed 
among Type-2 diabetes (T2D) patients. As a secondary objective, this study explores 
interaction between the demographic characteristics in influencing the identified barriers 
among T2D patients. 
 
3.3 Methods  
3.3.1 Study population 
We conducted a cross-sectional survey and chart review of patients with Type-2 
diabetes (T2D) from the Translating Research into Action for Diabetes (TRIAD) Cohort 
(62, 63). The survey, administered between 2005 and 2006, targeted subjects who had 
either good or poor control of three CVD risk factors, glucose, blood pressure, and lipids, 
as defined by published standards of care (64, 65). The written survey assessed a wide 
range of issues including patient perceptions of barriers to using medications as 
prescribed, which is the focus of this study. The chart review abstracted medical history 
information and specific diabetes-related health information for the previous 18 months 
from the point of the survey.  
In addition to the survey, data regarding medical history and related health 
information were obtained from chart reviews to identify and classify participants as 
having good or poor CVD risk factor control. Classification of quality of control used 
criteria set forth by the American Diabetes Association for three CVD risk factor 
measures: glycosylated hemoglobin A1c (HbA1c) for diabetes, systolic blood pressure 
(SBP) for hypertension, and low density lipoprotein cholesterol (LDL-c) for dyslipidemia 
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(64, 66). Poor CVD risk factor control was defined as failure in controlling any two of the 
three CVD risk factors, whereas good control was having all three risk factors within 
required targets. Poor diabetes control was defined as having an HbA1c ≥ 8 and the 
opposite was good control; poor hypertension control was defined as either a chart 
diagnosis of hypertension and an SBP ≥ 140 mm Hg, or two recent SBPs ≥ 160 mm Hg, 
while good hypertension control was defined as a chart diagnosis of hypertension and a 
most recent SBP < 140 mm Hg; poor dyslipidemia control was defined as a most recent 
LDL-c ≥ 130 plus either a chart diagnosis of dyslipidemia or a Statin prescription, or 
simply a most recent LDL-c ≥ 160, while good dyslipidemia control was defined as a 
chart diagnosis of dyslipidemia and a recent LDL-c < 130.  
Participants were adult (18 years or older) patients with Type-2 diabetes that were 
enrolled in a managed care health plan for more than 12 months and spoke either English 
or Spanish. Also, they had to have been diagnosed with diabetes, hypertension and 
dyslipidemia. In addition, they were required to have had at least one laboratory test for 
diabetes, blood pressure and lipids within the previous 12 months from the point of the 
survey. Participants were recruited from four TRIAD study centers (TRC): Indiana 
University, Kaiser Northern California, University of Michigan and University of 
California Los Angeles (UCLA). Approval for secondary analysis of the data was 
obtained from the Indiana University Purdue University Indianapolis institutional review 
board (IRB). For the original TRIAD study approval was obtained from IRBs at each 
participating site and informed consent obtained from each participant. Details of the 
TRIAD prospective study are described elsewhere (63). 
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3.3.2 Barriers 
Patients’ perceived barriers to using medication as prescribed by their healthcare 
provider, (termed “barriers”) were measured using the Murage-Marrero-Monahan 
medication barriers scale (4M scale). The 19-item 4M scale has demonstrated acceptable 
validity and reliability in assessing patients’ perceived barriers to medication use (67). 
The 4M scale is unique in that it focuses on general responses to all medications versus 
specific drugs. By using this approach, it addresses social desirability bias that is 
common when patients are queried about their use of specific medications by healthcare 
providers (68, 69). This tendency to affirm medication use is a common drawback of 
direct assessment methods of medication adherence (68). 
Five barrier constructs were assessed from each of the five domains of the 4M 
scale: poor personal access, poor communication with providers, poor understanding of 
and/or difficulty in taking medicine, side effects and system barriers to access. Each of 
the five domains was calculated as a mean of its barrier items. The overall mean 
calculated from the five domain means provided the overall barriers experience. To 
improve item completeness, missing items were imputed to the domain mean, if at least 
50% of items in a domain had responses. All items on the instrument were scored 1 
through 5 on a five-category response scale: “never”, “rarely”, “sometimes”, “usually”, 
and “always”, respectively. Higher mean scores indicated higher frequency of 
experiencing the barriers suggesting poor medication adherence.  
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3.3.3 Primary demographic measures 
Information on age, gender, race/ethnicity, education level, and household income 
were collected. Age was grouped in equal 10-year intervals, except to avoid sparse 
categories in response, the lowest and highest age groups had a wider range than 10 
years, and for the same reason, income responses were grouped in the survey and further 
compressed into three groups for analysis. 
 
3.3.4 Other potentially confounding covariate measures 
Other variables and potential confounders obtained or computed from the survey 
responses were smoking status, body mass index (BMI) group, duration with diabetes and 
participant’s TRIAD research center (TRC). Duration with diabetes was log-transformed 
to correct for its right-skewed distribution. All other covariates were categorical. 
 
3.3.5 Statistical analysis 
Descriptive characteristics of the sample population were calculated using 
frequencies and proportions for categorical variables, and means and standard deviations 
for continuous variables. For convenience, throughout the remainder of this paper we will 
use the term factors to refer to the independent variables in the models (i.e. the primary 
demographic variables and the potentially confounding covariates) for which the 
dependent variables are the different barrier scale scores.  Correlations between the 
primary demographic factors and between all factors together were calculated to examine 
redundancy from related factors.  
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Analysis of covariance (ANCOVA) was conducted to estimate the main influence 
from age, gender, race/ethnicity, education level and household income level on each of 
the five specific barriers and the overall barriers experience, while adjusting for 
potentially confounding variables. All models included all the five primary demographic 
factors and were adjusted for duration with diabetes, BMI group, smoking status and 
participant’s TRIAD research center (TRC). Significant categorical factors were 
examined for significant pairwise mean barrier differences using the simulation post-hoc 
test in the SAS GLM procedure. 
Based on an exploratory approach, potential interactions between the primary 
demographic factors were evaluated by including an interaction term in the ANCOVA 
models, using a separate model for each interaction test. A p-value of 0.05 was 
considered significant for all tests. All analyses were performed using SAS software 
(Version 9.4, SAS Institute, Cary, NC). 
 
3.4 Results  
From 1,137 surveys mailed out, 964 (85%) eligible participants responded to the 
survey and met the chart review inclusion criteria. Except for CVD risk all other 
variables were obtained from the survey. Participants tended to be older, mostly females, 
and had low annual household income (Table 3.1). Participants were similar in age and 
race/ethnicity to that observed in the U.S. diabetes prevalence population (2). Missing 
data was minimal for all variables, the highest being on household annual income. 
Participants had low barrier mean scores suggesting they had experienced only a few 
specific barriers (Table 3.1).   
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Table 3.1. Distribution of study population characteristics and identified barriers  
Patient characteristics 
All N=964  
n (%) 
Duration with diabetes [mean (SD)] 13 (10) 
CVD risk group  
Poor control of at least 2 CVD risk factors 405 (42%) 
Good control of all 3 CVD risk factors 559 (53%) 
Age groups  
18 to 39 years 19 (2) 
40 to 49 years 82 (8) 
50 to 59 years 267 (28) 
60 to 69 years 318 (33) 
70 to 79 years 217 (22) 
80 years and older 56 (6) 
Unknown 5 (1) 
Gender  
Females 552 (57) 
Males 412 (43) 
Education level  
Up to high school graduate or GED 453 (47) 
Some college or higher 499 (52) 
Unknown 12 (1) 
Household annual income level  
Low income (less than $40,000)  458 (47) 
Middle income ($40,000 to < $75,000) 190 (20) 
High income ($75,000 or more) 182 (19) 
Unknown 134 (14) 
Body mass index (BMI) group  
Normal 95 (10) 
Overweight 245 (25) 
Obese 419 (44) 
Morbidly Obese 139 (14) 
Unknown 66 (7) 
Race/Ethnicity  
non-Hispanic Caucasian 485 (50) 
non-Hispanic African American  196 (20) 
Other races 97 (10) 
Hispanic / Latino  139 (15) 
Unknown 47 (5) 
Smoking status  
Current Smoker 152 (16) 
Former Smoker 331 (34) 
Non-Smoker 428 (44) 
Unknown 53 (6) 
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Table 3.1. Continued   
Patient characteristics 
     All N=964  n 
(%) 
TRIAD research centers  
Kaiser Northern California 415 (43) 
Indiana University 235 (24) 
University of Michigan 151 (16) 
UCLA 163 (17) 
Barriers Mean (SD) 
Poor personal access 1.48 (0.61) 
Poor communication with providers 1.17 (0.43) 
Poor understanding of and/or difficulty taking medicine 1.17 (0.42) 
Side effects 1.24 (0.53) 
System barriers 1.23 (0.49) 
Overall Barrier Score 1.26 (0.39) 
 
N denotes the total number of participating patients. n denotes the total number of 
participants under each characteristic subgroup. % denotes percentage of the total 
population by the number in each characteristic subgroup. SD denotes standard deviation. 
GED denotes general educational development. BMI denotes body mass index. TRIAD is 
Translating Research Into Action for Diabetes. UCLA denotes University of California at 
Los Angeles. 
 
Primary demographic factors had low correlations with each other, except for 
education level and annual household income which had the highest though relatively 
moderate correlation (r = 0.43, p<0.0001) (Table 3.2).  Additionally, the absolute 
magnitude of the correlations of all factors, including the adjustment covariates not 
shown on table 3.2, ranged from r = 0.01 for age and gender to r = 0.43 for education and 
annual household income (absolute magnitude, median r = 0.08); again indicating 
moderately low correlations. Given that there was only minor redundancy among the 
factors, the four primary demographic factors and adjustment covariates were included in 
all ANCOVA models. 
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Table 3.2. Correlation between age, race/ethnicity, education and household income 
demographic factors 
Demographic factors 
Race / 
ethnicity 
Education 
Household 
income 
Gender 
Age group 0.04 - 0.16*** -0.24***         0.01 
Race/ethnicity  0.21*** 0.17***       -0.11** 
Education   0.43*** -0.19*** 
Household income    -0.25*** 
 
** denotes P<0.001. *** denotes P<0.0001 
 
Adjusted ANCOVA models revealed that all five specific barrier scores and the 
overall barrier score differed by age group (Table 3.3). Pairwise comparisons revealed 
that, in general barrier mean scores decreased with increasing age, suggesting that older 
patients experienced barriers to using medications less frequently than younger patients 
(Figure 3.1).  
 
 Table 3.3. Adjusted associations of demographic factors and specific barriers as well as the overall barrier experience 
assessed by the 4M scale 
a
 
 Poor 
personal 
access 
  
(model 1) 
Poor 
communication 
with providers 
 
(model 2) 
Poor 
understanding of 
and/or difficulty 
taking medicine 
(model 3) 
Side 
effects 
 
 
(model 4) 
System  
barriers 
 
 
(model 5) 
Overall 
Barrier 
Score 
 
(model 6) 
Overall F value 3.90**** 2.77**** 2.65**** 2.27** 2.67**** 3.54**** 
Adjusted R
2
 (%) (95 CI) 9 (5 to 14) 6 (2 to 10) 5 (2 to 10) 4 (1 to 8) 5 (2 to 10) 8 (4-13) 
Individual factors F-values
b
 
Age group    4.53***    4.29***    4.39***    4.68***  2.76*      5.63**** 
Comparison
b
 C, J, M, O C, J B, C C, D  C, D, O 
Gender 1.44 0.00 0.52 0.58 0.70 1.05 
Education level 1.35 0.66 0.15 0.79 0.24 0.19 
Household income  1.72   3.90* 1.04   3.15* 2.07   3.47* 
Comparison
b
  Q  Q  Q 
Duration 0.67 0.05 0.00 0.05 0.04 0.00 
BMI group    5.13** 0.22 1.94 0.74 0.80 2.17 
Comparison
b
 T, U      
Race/Ethnicity 0.55 1.86 1.70 1.09 0.50 0.85 
Smoking status 2.54 0.79 0.58 0.78 0.69 0.75 
TRIAD center 1.12 2.10 0.58 0.69   3.04* 1.37 
Comparison
b
     Z  
 
a
 Analysis of covariance (ANCOVA) models. 
b
 only significant comparisons of post-hoc simulation results are shown. % 
denotes percent. CI denotes confidence interval. BMI denotes body mass index. TRIAD is Translating Research Into Action 
for Diabetes.  
Age (in years) comparisons: A = 40 to 49  vs. 18 to 39 ; B =  40 to 49  vs. 50 to 59 ; C = 40 to 49  vs. 60 to 69 ; D = 40 to 49  
vs. 70 to 79 ; E = 40 to 49  vs. ≥80 ; F = 50 to 59  vs. 18 to 39 ; G = 50 to 59  vs. 60 to 69 ; H = 50 to 59  vs. 70 to 79 ; I = 50 to 
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 59  vs. ≥80 ; J = 60 to 69  vs. 18 to 39 ; K = 60 to 69  vs. 70 to 79 ; L = 60 to 69  vs. ≥80 ; M = 70 to 79  vs. 18 to 39 ; N = 70 
to 79  vs. ≥80 ; and O = ≥80  vs. 18 to 39 . 
Household annual income comparisons: P = high income ($75,000 or more) vs. middle income ($40,000 to < $75,000); Q = 
high income ($75,000 or more) vs. low income (less than $40,000); and R = middle income ($40,000 to < $75,000) vs. low 
income (less than $40,000). 
BMI group comparisons: S = morbidly obese vs. obese; T = morbidly obese vs. overweight; U = morbidly obese vs. normal 
weight; V = obese vs. overweight; W = obese vs. normal weight; and X = overweight vs. normal weight. 
TRIAD research center comparisons: Y = Kaiser Northern California vs. Indiana University; Z = University of Michigan vs. 
Indiana University; A1 = Kaiser Northern California vs. University of Michigan; A2 = Kaiser Northern California vs. UCLA; 
A3 = University of Michigan vs. UCLA; and A4 = UCLA vs. Indiana University. 
* P<0.05. ** P<0.01. *** P<0.001. **** P<0.0001. 
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Figure 3.1.Relationship between age and barriers mean scores. 
 “Pacss” denotes poor provider access barrier; “Prcom” denotes poor communication 
with providers barrier; “Pundt” denotes poor understanding and/or difficulty taking 
medicine; “Sdeft” denotes side effects barrier; “Sybrs” denotes system access barrier; and 
“Overall” denotes overall total barriers mean score. 
 
The poor communication with providers barrier score, the side effects barrier 
score and the overall barrier score differed by annual household income. All three barrier 
mean scores decreased with increasing annual household income (Figure 3.2). Patients 
from low annual household income (less than $40,000) had on average significantly 
higher mean scores than those from high household income ($75,000 or more) on the 
three barriers: poor communication with providers barrier, mean difference 0.15, 95% CI, 
0.02 to 0.27; side effects barrier, mean difference 0.15, 95% CI, 0.01 to 0.29; and overall 
barrier experience, mean difference 0.12, 95% CI, 0.01 to 0.23. 
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Figure 3.2. Relationship between annual household income and barriers mean scores. 
 “Prcom” denotes poor communication with provider barrier; “Sdeft” denotes side effects 
barrier; and “Overall” denotes overall total barriers mean score. 
 
Two covariates also were significant: the poor personal access barrier score 
increased with increasing BMI status. Morbidly obese patients had a significantly higher 
poor personal access mean score than overweight patients, mean difference 0.25, 95% CI, 
0.05 to 0.44; and normal weight patients, mean difference 0.32, 95% CI, 0.08 to 0.57. 
Additionally, the system barriers to access score differed by the participant’s TRIAD 
research center. System access barriers were significantly more common among Indiana 
University patients than University of Michigan patients (mean difference 0.20, 95% CI, 
0.02 to 0.37). The system access barrier mean score was highest among Indiana 
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University (1.28) patients, then UCLA (1.21) followed by Kaiser Northern California 
(1.15), and University of Michigan (1.09) had the lowest score. 
Potential interactions were identified between the primary demographic factors 
(Table 3.4). For the poor personal access barrier model only annual household income 
and race/ethnicity interaction was significant.  
In the poor communication with providers barrier model, the age and education 
interaction and the age and race/ethnicity interaction were separately significant. 
However, when both interactions were simultaneously included in the model only the age 
and race/ethnicity interaction (F=2.50, p=0.003) remained significant, suggesting the age 
and race/ethnicity interaction influenced the communication with providers barrier more 
than the age and education interaction.  
Similarly, for the poor understanding of and/or difficulty taking medicine barrier 
model, the age and education interaction, age and race/ethnicity interaction, and 
race/ethnicity and gender interaction were separately significant. But when 
simultaneously included in the model only the age and education (F=3.17), p=0.008) 
interaction remained significant. This suggests that the age and education interaction 
strongly influenced the poor understanding of and/or difficulty taking medicine barrier.  
For the side effects barrier model, the age and education interaction, age and 
race/ethnicity interaction, and age and gender interaction were separately significant. 
When included in the model together, both the age and race/ethnicity interaction (F=2.27, 
p= 0.0080) and the age and gender interaction (F=2.33, p=0.0411) remained significant. 
However, all interactions remained significant when any pair of the three interactions was 
included in the model simultaneously. This suggests all three interactions were 
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contributing unique explanation of the variation of the side effects barrier. In the system 
barriers to access model, only the age and education interaction was significant.  
Finally, on the overall barrier experience model, the age and education 
interaction, age and race/ethnicity interaction, and age and gender interaction were 
significant separately. When all three were included in the model, none was significant. 
However, the age and education interaction remained significant when included in the 
model with either the age and race/ethnicity interaction or the age and gender interaction. 
Also, when the age and race/ethnicity interaction and the age and gender interaction are 
concurrently included in the model both maintained significance. The finding suggests 
the age and education interaction influenced the overall barrier experience more than the 
other two interactions. 
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Table 3.4. Interactions between the primary demographic factors (age, race/ethnicity, education level and household income 
level) evaluated in separate ANCOVA models and their specific F-values.
 a
 
Possible interactions 
Poor 
personal 
access 
Poor 
communication 
with providers 
Poor understanding 
of and/or difficulty 
taking medicine 
Side 
effects 
System 
barriers 
Overall 
Barrier 
Score 
Age and Education 2.09 2.65* 3.61** 4.31*** 2.61* 4.33*** 
Age and Race/ethnicity 0.90 2.91*** 1.93* 2.74** 1.10 2.25** 
Income and Race/ethnicity 2.31* 0.20 0.36 0.61 1.21 0.47 
Age and Income 0.51 0.92 0.70 0.64 0.36 0.54 
Education and Income 0.59 0.38 0.42 0.21 0.66 0.34 
Education and Race/ethnicity 2.25 0.59 0.02 1.09 1.44 0.69 
Age and Gender 1.49 1.70 1.88 4.12** 1.60 2.81* 
Education and Gender 0.26 0.00 0.32 0.06 0.17 0.01 
Race/ethnicity and Gender 2.13 1.19 2.80* 2.12 1.07 1.44 
Income level and Gender 2.09 0.05 0.33 0.87 0.95 0.88 
 
* P<0.05. ** P<0.01. *** P<0.001. 
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3.5 Discussion 
Our study found that age and household income are independently associated with 
barriers to using medications as prescribed. Age was inversely associated with all 
barriers. This finding is consistent with studies by Rolnick et al., Yang et al. and others 
that found older patients had higher medication adherence than younger patients (60, 61, 
70, 71). Unlike younger patients, perhaps older patients are likely to take their treatment 
seriously, because they have more experience with the benefits of treating chronic 
conditions using medication. Also, the relationship may be attributed to older patients 
having greater understanding and acceptance that body immunity weakens with 
increasing age. It is also possible that older patients are less distracted by competing 
responsibilities such as job or children and thus, can focus more on complying with 
therapeutic interventions. 
Income was also inversely associated with two specific barriers, poor 
communication with providers and side effects. This finding agrees with existing 
literature that adherence increases with income, implying that barriers to medication use 
would be inversely related to income (60, 70, 72). It is likely that low income patients 
may be constrained with time from multiple jobs or less flexible work environment 
resulting in lack of adequate time to visit and discuss medication details with their 
providers. It also is likely that they are financially constrained, even with coverage, to 
continuously purchase their prescriptions as required. 
The observed interactions reveal an extended interplay between socio-economic 
status (SES) measures, plus age, gender and race/ethnicity in influencing the barriers 
(73). Education and income, two of the three cardinal measures of SES interact with age 
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and race/ethnicity, respectively.  In turn, age and race/ethnicity interact with each other 
and separately with gender. The interactions reveal important insights on how these 
demographic factors influence the barriers to using medication as prescribed by a 
healthcare provider. 
To interpret the significant interactions in this study, the adjusted means for 
barrier scores were examined descriptively within subgroups of factors. The age and 
education interaction suggests that younger patients with less than college education 
experienced the four barriers more frequently than younger patients with moderate to 
high education and all older patients. 
The age and race/ethnicity interaction indicate that younger minority patients had 
greater challenges with communication with providers, understanding of and/or difficulty 
taking medicine and side effects barriers than younger Caucasian patients. This may 
reflect the impact of poor language congruence between patients and providers. In 
situations where English is not the patient’s primary language, it is plausible that 
instruction about how to take medications or cautions about possible side effects may not 
be fully understood and thus, result in use disruption. Furthermore, the interaction agrees 
with previous findings that younger patients and minority patients have lower adherence 
(60, 61, 70, 71, 74-76). 
The age and gender interaction revealed that younger females report experiencing 
side effect barrier more often than their younger male counterparts and all older patients. 
Finally, the race/ethnicity and gender interaction further pointed that female minorities, in 
particular Hispanic/Latino and non-Hispanic African Americans, tend to have higher 
experience of poor understanding of and/or difficulty taking medicine barrier than female 
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non-Hispanic Caucasians and males in general. The observation agreed with previous 
findings on medication adherence (60, 61). Again this finding is potentially attributable to 
poor language congruence. 
Our study is not immune to limitations inherent in cross-sectional designs. First, 
there could be unidentified confounding factors that were not measured, which may 
influence the observed associations even though an attempt was made to adjust for all 
important confounders. Recall bias also could have been introduced when completing the 
surveys.  
Our findings are generalizable to patients with Type-2 diabetes and provide a 
foundation for higher level studies exploring the barriers as precursors of medication 
adherence. Specifically, development of models that predict each specific barrier would 
contribute to significant advancements in the clinical application of the barriers. 
Likewise, determining a threshold of the barriers score that would distinguish non-
adherent from adherent patients would also contribute significantly to the practical use of 
identified barriers toward improving medication adherence. 
 
3.6 Conclusion 
Age and income are inversely associated with patients’ perceived barriers to using 
medication as prescribed. Therefore, they should be considered when evaluating barriers 
to using medications as prescribed. Specifically, while age should be considered with all 
barriers identified by the 4M scale, income should be considered when the focus is 
communication with providers and/or side effects barriers. Nonetheless, both 
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demographic factors are important considerations when evaluating the overall barrier 
experience. 
Additionally, education, race/ethnicity and gender interact with age and/or income 
variably in influencing the identified barriers. Hence, they should be considered together 
with age and income in evaluating barriers. Our finding that age and income are 
associated with barriers is consistent with the finding of previous research that showed 
that both demographic factors are associated with medication adherence, which suggests 
a potential inverse relationship between barriers and medication adherence. 
Therefore, understanding the influence of these demographic factors on the 
barriers provide insight for developing tailored interventions with a greater likelihood of 
success. 
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CHAPTER 4 
 
PATIENT PERCEIVED BARRIERS TO MEDICATION USE AND 
CARDIOVASCULAR DISEASE RISK 
 
4.1 Abstract 
Background 
Medication non-adherence among patients with diabetes is associated with poor 
control of cardiovascular disease (CVD) risk factors. This study examines whether 
patient’s perceived barriers to using medications as indicators of medication adherence 
are associated with CVD risk factor control among Type 2 diabetes (T2D) patients 
treated for CVD. 
Method 
A cross-sectional study of T2D patients treated for CVD in the Translating 
Research into Action for Diabetes (TRIAD) study was conducted. From 964 patients who 
completed the Murage-Marrero-Monahan Medication barrier scale (4M scale) – a 
measure of perceived barriers to using medications as prescribed – 405 had poor control 
of at least two CVD risk factors (“cases”) and 559 had good control of all three CVD risk 
factors: glucose, lipids, and blood pressure (“controls”). Association between perceived 
barriers and CVD risk factors control was evaluated using multivariable logistic 
regression. 
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Results 
A unit increase in overall mean score on the 4M scale was associated with a 92% 
increase in the odds of having poor control of at least two CVD risk factors compared to 
good control of all three CVD risk factors (adjusted OR=1.92, 95% CI: 1.16 – 3.17). 
Analysis of specific perceived barriers revealed that poor personal access, side effects, 
and system access barriers were significantly associated with increased odds of poor 
control of CVD risk factors. 
Conclusion 
Increased barriers are associated with greater likelihood of having poorly 
controlled CVD risk factors. Assessing patient’s perception of barriers should be 
considered in the clinical care of T2D patients as indicators of medical utilization. 
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4.2 Introduction 
Diabetes is an established risk factor for cardiovascular disease (CVD) (19), the 
leading cause of death in the United States (15). Cardiovascular disease risk attributable 
to diabetes has increased from 5.4% to 8.7% of the U.S. population over the last half a 
century (16), and so has the enormous economic burden engendered by the two chronic 
and avoidable conditions (4, 17). Progression to CVD among diabetes patients has 
increased despite availability of medications with proven efficacy in controlling the three 
main precursors of CVD: hyperglycemia, hypertension and dyslipidemia (18, 20). 
It has been shown that less than 13% of patients with diabetes attained 
recommended goals on the three CVD risk factors: glycosylated Hemoglobin A1c 
(HbA1c), systolic blood pressure (SBP) and low density lipoprotein cholesterol (LDL-c) 
(19, 21). Medication non-adherence among patients with diabetes is one reason that has 
been postulated to explain the less than optimal targets on the three CVD risk factors 
(13). Research has shown that many persons with diabetes do not reliably take 
medication as prescribed (22). 
For interventions to improve medication adherence to be successful, 
understanding behaviors leading to non-adherence is essential. This study postulates that 
understanding patients’ perception of barriers to using medication as prescribed can 
indicate possible issues with medication adherence. With this premise, we sought to 
assess the association between patients’ perceptions of barriers to taking medications in 
general as prescribed and CVD risk. These findings will help in determining specific 
interventions to address medication adherence challenges (67). Additionally, the findings 
will provide evidence supporting the need to consider patient perceived barriers to 
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medication use in clinical care of diabetic patients, for example when considering 
treatment intensification (77). 
 
4.3 Methods 
4.3.1 Study population 
We conducted a cross-sectional study of patients with Type 2 diabetes (T2D) 
treated for CVD from the Translating Research into Action for Diabetes (TRIAD) cohort. 
Details of the TRIAD prospective study are described elsewhere (63). The survey 
administered between 2005 and 2006 included a written survey and chart reviews to 
determine CVD risk factor control. The written survey assessed barriers to medication 
use, patient activation, CVD risk perception, lifestyle behaviors, cost of medications, and 
participatory decision-making style among others. The chart review was used to abstract 
medical history and specific diabetes related health information for the past 18 months. 
Data used in this study are responses to barriers to using medication as prescribed (4M 
scale items) on the survey and CVD risk factor status from chart reviews. 
Participants were adult (18 years or older) patients with Type 2 diabetes that were 
enrolled in a managed care health plan for more than 12 months and spoke either English 
or Spanish. They had to have been diagnosed with hypertension and dyslipidemia. In 
addition, they were required to have had at least one laboratory test for diabetes, 
hypertension, and dyslipidemia within the past 12 months. Participants were recruited 
from one of four TRIAD research centers: Indiana University, Kaiser Northern 
California, University of Michigan and University of California Los Angeles (UCLA). 
Pregnant women and patients who did not meet the good and poor CVD risk control 
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criteria were excluded from the analysis for this paper. Approval for secondary analysis 
of the data was obtained from the Indiana University Purdue University Indianapolis 
institutional review board (IRB). For the original TRIAD study, approval was obtained 
from IRBs at each participating site and informed consent obtained from each participant 
(78). 
 
4.3.2 Outcome measure 
CVD risk was defined as good or poor based on criteria set forth by the American 
Diabetes Association that defines cut-points for three risk factor measures: glycosylated 
Hemoglobin A1c (HbA1c) for diabetes glycemic control, systolic blood pressure (SBP) 
for hypertension, and Low density lipoprotein cholesterol (LDL-c) for dyslipidemia (64, 
66). Poor diabetes control was defined as having an HbA1c ≥ 8 and the opposite was 
good control. Poor hypertension control was defined as either a chart diagnosis of 
hypertension and an SBP ≥ 140 mm Hg, or two recent SBPs ≥ 160 mm Hg, while good 
hypertension control was defined as a chart diagnosis of hypertension and a most recent 
SBP < 140 mm Hg. Poor dyslipidemia control was defined as a most recent LDL-c ≥ 130 
plus a chart diagnosis of dyslipidemia, or a Statin prescription and most recent LDL-c ≥ 
130, or simply a most recent LDL-c ≥ 160, while good dyslipidemia control was defined 
as a chart diagnosis of dyslipidemia and a recent LDL-c < 130. 
Cases were defined as patients having poor control on at least two of the three 
CVD risk factors, whereas controls had values within the good control range on all the 
three CVD risk factors. Classification was conducted and adjudicated by a panel of four 
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physicians who reviewed the chart data. Based on the criteria 405 patients met the criteria 
for poor control and 559 patients met the criteria for good control. 
 
4.3.3 Main Exposure 
Barriers were defined as obstacles that, from the respondent’s perspective, hinder 
compliance with recommendations for using medications as prescribed by their 
healthcare provider. Barriers were measured using the Murage-Marrero-Monahan 
Medication barriers scale (4M scale), an instrument for assessing patients’ perceived 
barriers to using medications as prescribed (67). The 19-item scale has demonstrated 
acceptable validity and reliability in assessing overall barriers experience or five specific 
barrier domains, namely poor personal access, poor communication with providers, poor 
understanding of and/or difficulty taking medicine, side effects, and system barriers to 
access. The items assess whether and how often the patient experiences a series of 
possible barriers to taking medication as prescribed. A five-category response scale is 
used for all items: “Never”, “Rarely”, “Sometimes”, “Usually” and “Always”. The score 
for each item ranged from 1 to 5, respectively (67). The instrument was designed to 
reduce false positive reporting of medication use resulting from social desirability bias, a 
common drawback of direct assessment methods of medication adherence. This is 
accomplished by assessing experiences with barriers to using medications in general 
without asking about specific medications during the encounter. Rather, the respondents 
are asked if they have ever run out or ever missed a dose of any of their medicines within 
the past 6 months and how often they experience the barriers listed. The overall mean 
score, the mean of the five subscale means, was intended as a measure of the frequency 
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of overall barriers experience. Higher scores on the 4M subscales and overall mean 
barrier score indicated increased frequency of experiencing barriers to medication use. 
 
4.3.4 Other measures 
Age, gender, race/ethnicity, education level, smoking status, income level, body 
mass index (BMI), duration with diabetes, and participant’s TRIAD research center 
(TRC) were collected as potential confounders or important adjusting covariates. Age 
was categorized into ten-year intervals, except the first and last age groups that had wider 
age ranges to avoid sparse categories in response, and for the same reason income 
responses were grouped in the survey and further compressed into three groups for 
analysis. BMI was grouped into four groups: normal (BMI ≤ 24kg/m2), overweight (BMI 
25 to < 30kg/m
2
), obese (BMI 30 to <40kg/m
2
), and morbidly obese (BMI ≥ 40kg/m2). 
Except for duration with diabetes, all other covariates were categorical. 
 
4.3.5 Statistical analysis 
Descriptive characteristics of cases and controls were calculated using frequencies 
and proportions for categorical variables, and means and standard deviations for 
continuous variables.  Continuous variables were examined for normality. Only duration 
with diabetes was skewed and was log-transformed. 
To improve completeness of domain mean scores, missing items were imputed to 
the domain mean if at least 50% of items in a domain had responses. When computing 
the overall barriers score, all five domain scores were required to be non-missing. 
Missing scores were distributed across the five domains. Without imputation of domain 
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scores, the overall mean barrier score were missing in 20% of cases and 17% of controls. 
After imputation of domain scores, missing data on the overall barrier scores were 
reduced to 6% among cases and by 4% among controls.  
Unadjusted odds ratios (ORs) and adjusted ORs for the association between 
identified barriers and CVD risk control were computed using logistic regression. The 
unadjusted OR was computed by entering a single barrier scale score into the model as 
the sole independent variable without other covariates. Adjusted ORs for the barriers 
score were controlled for age, gender, race/ethnicity, education level, smoking status, 
income level, BMI group, duration with diabetes and participant’s TRC. All are either 
confounders or important covariates of CVD risk. Each barrier domain and overall score 
was entered in separate models because the correlated domain scored would have created 
a multicollinearity problem if all domain scores were entered into the same model. 
Analysis of the association between specific barriers and CVD risk control was 
examined by computing unadjusted and adjusted ORs of each barrier separately. A p-
value of 0.05 was considered significant. All analyses were performed using SAS 
software (Version 9.4, SAS Institute, Cary, NC). 
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4.4 Results 
4.4.1 Participants 
From the 1,137 surveys mailed out and chart reviews, 964 (85%) eligible 
participants responded to the survey and met the criteria for cases and controls (Table 
4.1). Except for CVD risk control classification that was obtained from chart reviews, all 
other variables were obtained from the survey. Cases were on average slightly, but 
significantly, younger and had longer duration living with diabetes than controls. Also 
cases reported a slightly higher proportion of low household income (<$40,000) than 
controls. 
  
70 
Table 4.1. Characteristics of participants by CVD risk control group: poor control 
(cases) vs. good control (controls). 
Patients  
Characteristics 
Cases: Patients 
with poor control 
of CVD risk 
factors (N=405) 
n (%) 
Controls: patients 
with good control 
of CVD risk 
factors (N=559) 
n (%) 
Chi-square 
and 
Significance 
level 
Duration with diabetes
†
 14 (10.4) 12 (10.5)  2.51* 
Age     19** 
18 to 39 years 11 (3) 8 (1)  
40 to 49 years 48 (12) 34 (6)  
50 to 59 years 113 (28) 154 (28)  
60 to 69 years 127 (31) 191 (34)  
70 to 79 years 91 (22) 126 (22)  
80 years and older 14 (3) 42 (8)  
Unknown 1 (1) 4 (1)  
Gender   6* 
Female 250 (62) 302 (54)  
Male 155 (38) 257 (46)  
Race/ethnicity   39*** 
Non-Hispanic Caucasian 164 (41) 321 (58)  
Non-Hispanic African 
American 
114 (28) 82 (15)  
Other races 50 (12) 47 (8)  
Hispanic/Latino 60 (15) 79 (14)  
Unknown 17 (4) 30 (5)  
Education   3 
Up to high school 
graduate or GED 
202 (50) 251 (45)  
Some college or higher 
education 
197 (49) 302 (54)  
Unknown 6 (1) 6 (1)  
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Table 4.1. Continued. 
Patients  Characteristics 
Cases: Patients 
with poor control 
of CVD risk 
factors (N=405) 
n (%) 
Controls: patients 
with good control 
of CVD risk 
factors (N=559) 
n (%) 
Chi-square 
and 
Significance 
level 
BMI group   7 
Normal (BMI ≤ 24kg/m2) 33 (8) 62 (11)  
Overweight (BMI 25 to < 
30kg/m
2
) 
92 (23) 153 (27)  
Obese (BMI 30 to 
<40kg/m
2
) 
186 (46) 233 (42)  
Morbidly obese (BMI ≥ 
40kg/m
2
) 
62 (15) 77 (14)  
Unknown 32 (8) 34 (6)  
Household Income   10* 
Low income (less than 
$40,000) 
209 (52) 249 (45) 
 
Middle income ($40,000 to 
< $75,000) 
64 (16) 126 (22) 
 
High income ($75,000 or 
more)  
70 (17) 112 (20) 
 
Unknown 62 (15) 72 (13)  
Triad Research Centers   41*** 
Kaiser Northern California 201(50) 214 (38)  
Indiana University 116 (29) 119 (21)  
University of Michigan 34 (8) 117 (21)  
UCLA 54 (13) 109 (20)  
Smoking Status   4 
Current Smoker 67 (17) 85 (15)  
Former Smoker 127 (31) 204 (36)  
Non-Smoker 184 (45) 244 (44)  
Unknown 27 (7) 26 (5)  
 
†
 Summary presented as mean and standard deviation, and the statistical test value is the 
T value from two-sided t test. CVD denotes Cardiovascular Disease.  n denotes frequency 
by specified characteristic.  % denotes percentage. GED denotes General Educational 
Development. BMI denotes body mass index. UCLA denotes University of California, 
Los Angeles. * p<0.05, ** p<0.01 and *** p<0.001. 
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Cases had a higher overall barrier score on the 4M scale than controls and the 
difference was statistically significant (Table 4.2). A similar trend was observed on all 
specific subscale barriers mean scores, indicating that the barriers were more common 
among cases than among controls.  
 
Table 4.2. Overall barrier mean score and subscale barriers mean scores by CVD risk 
control group: poor control (cases) vs. good control (controls). 
Overall and specific 
subscale barriers 
Cases: Patients 
with poor 
control of CVD 
risk factors. 
mean (SD) 
Controls: 
patients with 
good control of 
CVD risk 
factors. 
 mean (SD) 
Mean difference 
(95% CI) 
Overall barrier score 1.3 (0.4) 1.2 (0.3) 0.1 (0.08-0.19)*** 
Poor personal access 1.6 (0.7) 1.4 (0.5) 0.2 (0.11-0.28)*** 
Poor communication with 
providers 
1.2 (0.5) 1.1 (0.4) 0.01 (0.03-0.15)**  
Poor understanding of 
and/or difficulty taking 
medicine 
1.2 (0.5) 1.1 (0.3) 0.1 (0.06-0.18)*** 
Side effects 1.3 (0.6) 1.2 (0.5) 0.2 (0.08-0.23)*** 
System barriers to access 1.3 (0.5) 1.2 (0.4) 0.1 (0.04-0.17)** 
 
CVD denotes cardiovascular disease. SD denotes Standard Deviation. CI denotes 
confidence interval. ** p<0.01 and *** p<0.001.  
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Table 4.3. Unadjusted and adjusted odds ratios from logistic regressions modeling the 
probability of poor control of CVD risk factors from patients’ perceived barriers to 
medication use. 
Overall and specific subscale 
barriers  
Unadjusted 
ORs 
(95% CI) 
Adjusted 
ORs 
(95% CI) 
Overall barrier score 2.25*** (1.48-3.41) 1.92* (1.16-3.17) 
Poor personal access 1.58*** (1.22-2.05) 1.52* (1.11-2.07) 
Poor communication with 
providers 
1.63** (1.13-2.35) 1.42 (0.93-2.19) 
Poor understanding of and/or 
difficulty taking medicine 
1.75** (1.21-2.54) 1.43 (0.91-2.26) 
Side effects 1.78*** (1.24-2.46) 1.57* (1.06-2.30) 
System barriers to access 1.70** (1.22-2.35) 1.47* (1.01-2.14) 
 
CVD denotes cardiovascular disease. CI denotes confidence interval. OR denotes odds 
ratio. Adjusting factors are age group, gender, education level, household annual income 
level, duration with diabetes, BMI status group, race/ethnicity, smoking status and 
participants TRIAD research center. * p<0.05, ** p<0.01 and *** p<0.001.  
Note: For all adjusting factors only duration of living with diabetes (p=0.0001), 
race/ethnicity (p=0.003) and Triad research center (p<0.0001) were significant. 
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The overall barrier score remained significant even after adjusting for other 
factors (Table 4.3). A one-unit increase in the 5-point overall mean of patients’ perceived 
barriers to using medication as prescribed by their healthcare provider was associated 
with a 92% increase in the odds of having poor control of two or more of the three 
cardiovascular disease risk factors as opposed to good control of all three CVD risk 
factors, after adjusting for all other covariates in the model (adjusted OR=1.92, 95% CI: 
1.16 – 3.17; p<0.05). Duration with diabetes (OR=4.77, 95% CI: 3.47-7.13; p=0.0001), 
race/ethnicity (p=0.0013) and participant’s Triad research center (p<0.0001) were 
significant adjusting factors in the model.  
For subscale analyses, even though all unadjusted associations between the five 
specific barriers on the 4M scale and probability of poor control of CVD risk were 
significant, only poor personal access, side effects and system barriers to access specific 
barriers maintained significance after adjusting for all other covariates (Table 4.3). A unit 
increase in poor personal access barrier mean score was associated with a 52% increase 
in the odds of having poor control on at least two or the three CVD risk factors 
(OR=1.52, 95% CI: 1.11-2.07; p<0.01). A unit increase in side effects barrier mean score 
was associated with a 57% increase in the odds of having poor control on at least two or 
the three CVD risk factors (OR=1.57, 95% CI: 1.06-2.30; p<0.05). A unit increase in 
system barriers to access mean score was associated with a 47% increase in the odds of 
having poor control on at least two of the three CVD risk factors (OR=1.47, 95% CI: 
1.01-2.14; p<0.05). 
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4.5 Discussion  
Our study illustrates that patients’ perceptions of barriers that interfere with taking 
their medication as prescribed are associated with poor CVD risk factor control. 
Specifically, on average, patients with diabetes who experienced barriers more frequently 
as measured by the 4M scale had higher odds of having poorly controlled HbA1c, SBP, 
or LDL-c compared to those who experienced barriers less frequently. The findings 
agreed with previous research relating medication non-adherence to increased CVD 
hospitalization (59) and medication adherence to reduced vascular events (79, 80). These 
previous research when taken together with our findings, suggests that patients’ perceived 
barriers are specific determinants or drivers of medication adherence issues.  Our findings 
are important not only in confirming that patients’ perceived barriers helps to explain 
CVD risk control but also in identifying barriers on which specific interventions can be 
designed (67). The association corroborates the need to first consider barriers to 
medication use before commencing treatment intensification among patients with 
diabetes (13, 77, 81, 82). 
Race/ethnicity, duration of living with diabetes and participants recruitment site 
were significant correlates of poor CVD risk control in the overall barrier score model. 
They agreed with previous research that duration of diabetes increases cardiovascular 
mortality (83). Additionally, minorities, particularly non-Hispanic African Americans, 
have higher odds of poor CVD risk compared to non-Hispanic Caucasians (84). 
Significance of the participant recruitment site suggested that regional differences, 
perhaps socio-economic or clinical practice, may affect CVD risk control. 
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Analysis of the 4M subscales revealed three specific barriers – poor provider 
access, side effects and system barriers to access – were significantly associated with 
poor CVD risk factor control. Therefore, focusing interventions to this population on the 
three barriers is likely to yield improvement in medication adherence, control of CVD 
risk factors, and eventually improvement in CVD risk factor control. 
The study also had unique strengths. First, it minimized social desirability bias by 
indirectly focusing on barriers of the 4M scale rather than inquiring about adherence to 
specific medications. The 4M scale is a unique measure in that it can identify specific 
sources of barriers that can inhibit appropriate utilization of medications. This is a 
necessary step in developing interventions to improve medication utilization. Second, the 
study was conducted on a large, national multisite sample of well characterized patients 
from wide regional, clinical, racial-cultural backgrounds. Therefore, the study findings 
can be generalized to adult patients who have Type 2 diabetes, CVD and healthcare 
access. 
Similar to other cross-sectional studies there may be potentially uncontrolled 
confounders not adjusted for in the study. The potential for recall bias is introduced by 
retrospectively assessing the barriers using the 4M scale. Also, the potential for 
misclassification bias may have been introduced by lack of information whether patients 
were seated or standing during SBP measurement, and lack of information whether 
patients were fasting before the laboratory measures. Finally, inherent in cross-sectional 
study design, the study could not establish temporal relationships between the barriers 
and CVD risk factors control. 
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Critical to the importance of these findings in addressing medication adherence 
through clinical care and public health interventions, there is need for future studies to 
prospectively establish the temporal relationships between patients’ perceived barriers to 
using medication as prescribed, as drivers of medication adherence, and CVD risk 
factors. Also, there is need for a randomized clinical intervention study to assess the 
effectiveness of interventions targeting barriers identified by the 4M scale. 
 
4.6 Conclusion 
This study demonstrated that increased experiences of barriers to using 
medication as prescribed is associated with greater likelihood of having poor control of 
CVD risk factors. The association provides scientific evidence supporting the need to 
consider assessing patient’s perception of barriers to medication use as indicators of 
medical utilization in the clinical care of Type 2 diabetes patients treated for CVD. For 
practical importance, the finding suggests that targeted interventions against identified 
barriers to medication use would contribute to slowing or stopping progression to CVD. 
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CHAPTER 5 
 
DISCUSSIONS AND CONCLUSIONS 
 
Findings from the three studies provide important insights into the role of barriers 
on medication adherence among Type-2 diabetes patients. First, the developed 19-item 
Murage-Marrero-Monahan Medication barriers scale (4M scale) was established as a 
valid and reliable instrument for assessing patients’ perceived barriers to using 
medication as prescribed by a healthcare provider. The frequencies of the barriers 
measured by the instrument were found to be associated with age and income. 
Additionally, education, gender, race/ethnicity and geographic location of patients 
modified the association of age and income on barriers. Finally, greater barriers were 
associated with poorer CVD risk control. Comparing these findings with those of 
medication adherence from previous research illuminates several important implications 
on the adequacy of assessing barriers to using medication as prescribed by a healthcare 
provider as an alternate to assessing medication adherence. 
The association between barriers and control of CVD risk factors agreed with 
previous studies which found poor medication adherence was also associated with CVD 
(59, 79, 80). This agreement and the understanding that poor control of CVD risk factors 
is an intermediate stage in the natural history of CVD implies that barriers can indicate 
issues with medication adherence as conceptualized. 
Additionally, the finding that barriers were associated with age and income also 
agreed with other studies that have demonstrated medication adherence is associated with 
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both age and income (60, 61, 70-72).  By further examining the direction of associations 
for both barriers and medication adherence with respect to CVD and the two 
demographic factors separately, the postulated counter-directional relation becomes 
evident. When barriers increase, CVD risk increases, while when medication adherence 
decreases, CVD risk increases and vice versa. For the demographic factors, when age 
increases barriers are fewer whereas medication adherence is higher. Likewise, when 
income increases, barriers are fewer whereas medication adherence is higher. The 
observed counter-directional associations imply existence of a plausible link between 
barriers and medication adherence and suggest that the two are possibly inversely related.  
Barriers may potentially influence medication adherence.  Because previous 
studies have shown that medication adherence is a modifiable behavior, the potential 
influence between barriers and medication adherence presents an opportunity for using 
tailored interventions on identified barriers to improve medication adherence (29). 
Consequently, the personalized interventions on identified barriers through a cascade of 
responses have a higher likelihood of success in improving health outcomes, for example 
slowing down or reducing CVD outcomes. 
Finally, the fact that the association of barriers and both age and income agrees 
with the association of medication adherence and both demographic factors, underscores 
the need for considering age and income when assessing and interpreting barriers as an 
alternate to medication adherence. 
Overall, findings from this study, that patients’ perceived barriers to medication 
use are a potential alternative to directly measuring medication adherence, expose many 
opportunities for future research studies. To broaden evidence in using the 4M scale for 
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assessing barriers will require the following: psychometric evaluation of the tool among 
other patient populations and in other regions for a wider application, criterion validity 
evaluation for evidence that it is a reasonable proxy for adherence, and responsiveness 
evaluation for evidence on its ability to detect change in patients’ perceived barriers 
following an intervention. Furthermore, studies to establish temporal relationship 
between reported barriers to medication use and the cardiovascular outcome would 
provide additional indication on the interrelationship between the barriers and medication 
adherence. Likewise, a randomized controlled trial on the effectiveness of interventions 
targeting identified barriers on the 4M scale would also corroborate the clinical 
importance of considering perceived barriers during clinical encounters. Equally 
important, studies to develop models that include readily observable demographic 
characteristics in predicting specific barriers in the 4M scale would enhance 
interpretation and generalizability of the 4M scale scores. Additionally, future studies to 
determine a threshold on the 4M scale score that distinguish potentially non-adherent 
patients from adherent patients would enhance interpretation of the 4M scale and its 
practical use for measuring patients’ perceived barriers to medication use as prescribed. 
In conclusion, the developed 19-item Murage-Marrero-Monahan Medication 
barriers scale (4M scale) has acceptable psychometric properties as an adequate 
assessment instrument for assessing patients’ perceived barriers to medication use as 
prescribed by their healthcare provider. The tool provides novel information that can 
facilitate discussions between patients and their providers during clinical encounters. 
Most importantly, comparisons of findings from this dissertation associating 
barriers to demographic factors and CVD risk control and those of previous studies 
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associating medication adherence to demographic factors and CVD risk corroborate the 
hypothesis that barriers indicate possible issues with medication adherence. Therefore, 
assessing patient’s perceived barriers to using medications as prescribed by their 
healthcare provider is a plausible alternative for assessing medication adherence. By 
assessing barriers in a generalized context, the 4M scale circumvents social desirability 
bias introduced by directly confronting patients about their medication use, and captures 
information beyond the immediate use which could be confounded by other prevailing 
factors, for example, closeness to an appointment. Additionally, by identifying specific 
barriers to medication use, care providers have the added opportunity of personalizing 
interventions to reduce or eliminate the barriers. Thus, the tailored interventions will have 
increased likelihood of success. 
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APPENDIX A 
DIABETES MEDICINES SURVEY 
Note: Select sections extracted from the diabetes medicines survey used to collect data 
for development and psychometric evaluation study discussed in chapter 1. 
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APPENDIX B 
TRIAD FOCUSED SURVEY CHART REVIEW INSTRUMENT 
VERSION 2.0 
 
Note: Extracted sections of the original chart review instrument used for studies in 
chapter 3 and 4. The complete instrument is available online at 
http://www.triadstudy.org/instruments_tools/pdf/focused_surv_chart_review.pdf 
 
 
 
 
  
88 
 
 
 
  
89 
 
 
  
90 
APPENDIX C 
CVD RISK FACTOR PATIENT WRITTEN SURVEY 
 VERSION 0206 
 
Note: Extracted sections of the original survey used for studies in chapter 3 and 4. The 
complete survey is available online at 
http://www.triadstudy.org/instruments_tools/pdf/cvd_risk_patient_written_survey.pdf 
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